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Abstract 
 
 Cell Division Cycle Associated Protein 7 (CDCA7) is a novel protein with poorly 
defined physiological significance. The proximity labeling method known as Biotin 
Identification (BioID) was used to determine candidate interactors of CDCA7. Mass 
spectrometry identified the microtubule spindle assembly protein TPX2 as a novel candidate 
interactor of CDCA7. Immunoprecipitation experiments verified interaction between CDCA7 
and TPX2. The region of interaction was isolated to residues 195-204 of CDCA7. Based on 
inhibitor experiments, Aurora A kinase activity coincides with the phosphorylation of CDCA7 
at the threonine (T) 163 residue. During mitosis, CDCA7 colocalizes with TPX2, localizes at 
centrosomes and undergoes phosphorylation at T163. These findings and previous findings 
in literature place CDCA7, TPX2 and potentially Aurora A kinase together within the context 
of mitosis. The results here demonstrate the direct interaction between CDCA7 and TPX2, 
and highlight residue T163 of CDCA7 as a prospective phosphorylation target of Aurora A 
kinase.   
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Chapter I: Introduction and Research Objectives 
 
Cancer 
 
 Cancer encompasses a variety of diseases involving loss of cell cycle control, aberrant 
cell proliferation and metastasis. Cancer is prevalent throughout the world, with the most 
common types manifesting in lung, breast and colorectal regions. The most deaths occur 
with lung, liver and stomach cancers. The World Health Organization reports 8.2 million 
cancer-related deaths and 14.1 million new diagnosed patients in 2012.1 If the demographic 
trends for gender, income and age in 2012 are kept constant, there will be 21.6 million new 
diagnosed cases of cancer by 2030, a 53% increase from 2012.2 In Canada, there is a 50% 
chance that citizens will develop cancer in their lifetime and in 2017, 206, 200 new cases of 
cancer are expected to occur. Cancer is the leading cause of pathophysiological mortality in 
Canada, accounting for 30% of all deaths.3  
The Oncogene c-Myc 
 
 A well-documented protooncogene is cellular-Myc (c-Myc) which will be referred to 
as Myc hereafter. The myelocytomatosis (Myc) gene, which encodes the Myc protein, may be 
the most well studied gene/protein so far. Between the years 1964-2012, more than 22,000 
primary and review articles on Myc have been released. Millions of dollars in research are 
dedicated to Myc, with a publication rate of 3 publications per day.4 The Myc protein 
functions primarily as a transcription factor that contains an amino (N) terminal 
transactivation domain. Myc associates with the transcription factor Max through a basic 
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helix loop helix domain5. Myc binding sites are present on 3465 genes, which accounts for 
approximately 15% of the human genome6. 
 In normal cells, the Myc gene is subjected to a rigid degree of regulation though 
factors that are both genetic and epigenetic. Myc aids and drives tumorigenesis by 
deregulating several processes which include but are not limited to cell adhesion and 
cytoskeletal regulation5, Deoxyribonucleic acid (DNA) replication7, DNA transcription8, 
protein synthesis9, angiogenesis10, the immune response11, cell metabolism and growth12, 
and apoptosis13. Myc-induced cancers are said to be addicted to the Myc oncogene, with 
suppression of the oncogene reversing the tumorigenic phenotypes14.  Myc deregulation is 
estimated to occur in more than 70% of cancers15. 
 Novel target genes of Myc have been identified, however the functions of several 
novel genes are yet to be determined. In one study, the Myc allele was conditionally 
expressed in lymphoma cell lines and microarray analysis was performed to identify target 
genes of Myc. The messenger ribonucleic acid (mRNA) expression of target genes was 
determined through experiments where the Myc gene was stimulated, deactivated and then 
reactivated. The candidate genes were then subjected to chromatin immunoprecipitation 
(ChIP) in order to determine which gene promoters were enriched with Myc. These 
experiments found 89 genes that were direct Myc target genes and 27 of these genes were 
non-annotated sequences (unknown function).16 Comparison of gene expression between 
Rat1a fibroblasts and Rat1a fibroblasts stably expressing the Myc oncogene identified 20 
differentially expressed genes.17 The most differentially expressed gene was named JPO1.18   
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CDCA7 
 
Gene Expression Regulation via Myc or E2F and Transcription Factor Capability 
 
 The JPO1 gene maps to chromosome 2q31 and consists of 2.5 kilo-basepairs which 
translates a 47 kilo-Dalton (kDa) protein. The protein contains a leucine zipper domain and 
a carboxyl (C) terminal cysteine rich domain. Cell lines stably expressing the Myc gene fused 
to the estrogen receptor (ER) showed that JPO1 mRNA expression increases when MycER 
cells are exposed to 4-hydroxytamoxifen (estrogen variant). Inhibition of protein synthesis 
with cycloheximide still resulted in an increase in JPO1 mRNA expression. As a result, JPO1 
is a direct target gene of Myc which does not require the synthesis of an intermediate protein. 
The expression of JPO1 mRNA was measurable in the small intestine, thymus and colon, and 
sparse mRNA expression was found in bone marrow, spleen and leukocytes.18 The JPO1 gene 
consists of 9 exons and ChIP experiments with several fragments of the JPO1 gene identified 
enrichment of Myc at two canonical E-boxes (5’-CACGTG-3’) within intron 1.19  
 The expression of the transcription factor E2F1 resulted in an increase in JPO1 mRNA 
expression. Various promoter constructs of the JPO1 promoter linked to a luciferase reporter 
gene were generated. Deletion of the E2F consensus binding site upstream of the JPO1 
transcription start site (TSS) resulted in no luciferase activity.20 E2F1, E2F2 or E2F3 
expression alone can force quiescent cells into the S phase of the cell cycle, where as E2F4 
and the DP-1 transcription factor are required to transition quiescent cells into S phase.21 
E2F1, E2F2, E2F3 and E2F4 upregulate JPO1 expression, as evidenced by luciferase reporter 
assays. ChIP Experiments using the region adjacent to the TSS of JPO1, showed that E2F1, 
E2F2 and E2F4 are enriched at the E2F consensus binding sites.20  
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 A similar protein, named JPO2 shares 45% homology with JPO1. Both JPO1 and JPO2 
share similar C-terminal cysteine rich domains (88% homology) which encodes a putative 
zinc finger domain.22 JPO2 has been shown to bind the monoamine oxidase A promoter at 
Sp1 sites and causes transcriptional repression as well as reductions in protein activity. The 
level of repression correlated to the level of JPO2 protein expression.23 A construct 
containing the Gal4 DNA binding domain and the C-terminal region of JPO1 (residues 247-
371) was created. This construct successfully induced expression of a construct with 5 Gal4 
DNA binding sites and a TATA box fused to a luciferase reporter gene. Therefore, the C-
terminal domain of JPO1 contains transcriptional capabilities.20  
Protein Interactions with Myc or 14-3-3 and Akt Phosphorylation  
   
JPO2 directly interacts with Myc in 293TV cells with the leucine zipper domain, binds 
to Myc at chromatin and colocalizes with Myc in the nucleus.22 The human genome 
nomenclature committee has adopted the name Cell Division Cycle Associated protein 7 
(CDCA7) for JPO1, and found that CDCA7 expression peaks around the G1/S transition of the 
cell cycle.24 JPO1 will be referred to as CDCA7 hereafter. Residues 146 to 170 of CDCA7 have 
been shown to interact with residues 274-440 of Myc. The region of CDCA7 that interacts 
with Myc contains a bipartite nuclear localization sequence (NLS) which spans residues 160-
190.25 The region also contains an Akt phosphorylation consensus site. The consensus site 
requires serine or threonine as the main residue with arginine at residues -5 and -3 as well 
as a large hydrophobic residue at +1.26 Threonine 163 of CDCA7 matches this perfectly 
(RPRRRTF). Threonine 163 (RRRTFP) also matches the 14-3-3 mode I phosphorylation 
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binding site25, which requires serine or threonine as the central residue, arginine at -3 and 
proline at +2.27  
Overexpression of Myc in cells subjected to serum withdrawal leads to apoptosis.28 
Stable expression of CDCA7 in Rat1a fibroblasts that are already stably expressing Myc 
(Rat1a-Myc) leads to an increase in serum-withdrawal induced apoptosis. However, deletion 
of the NLS abolishes apoptosis even in the presence of Myc overexpression. The NLS deletion 
may be acting as a dominant negative mutant29 that potentially binds to the same promoters 
as Myc but does not bind to Myc itself. If Rat1a-Myc cells stably express short hairpin RNA 
(shRNA) which targets and knocks down CDCA7 expression, the number of apoptotic cells 
decreases and the cells exhibit less apoptotic morphology, even with Myc overexpression25. 
Thus, Myc and CDCA7 may induce apoptosis together, and interaction of Myc and CDCA7 is 
a requirement for serum withdrawal induced apoptosis. 
Two-dimensional tryptic digest of wildtype (WT) CDCA7 and the threonine 163 to 
alanine (T163A) CDCA7 mutant showed that T163 of CDCA7 is phosphorylated. WT CDCDA7 
primarily localizes to the nucleus with some cytoplasmic staining, while T163A CDCA7 only 
localizes to the nucleus. WT CDCA7 was stimulated by fibroblast growth factor (FGF) and 
platelet-derived growth factor (PDGF), while T163A CDCA7 was not. Both FGF and PDGF led 
to increases in cytoplasmic localization and phosphorylation of T163 (pT163). The putative 
NLS of CDCA7 was subjected to various deletions and mutations that led to cytoplasmic 
localization. Thus, CDCA7 contains a bonafide bipartite NLS.25  
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The adapter protein 14-3-3 binds to phosphorylated residues and can mask the NLS 
of target proteins, which leads to the sequestration of these proteins in the cytoplasm.27 WT 
CDCA7 binds to 14-3-3 and localizes to both the nucleus and cytoplasm. The T163A CDCA7 
mutant does not bind 14-3-3 and only localizes to the nucleus. Replacement of 20 amino 
acids around T163 with the R18 peptide that constitutively binds 14-3-3 through its aspartic 
acid (D) and glutamic acid (E) residues30, causes cytoplasmic localization. Mutation of the DE 
residues with lysine (K) abolishes 14-3-3 binding and results in nuclear localization.  Thus, 
pT163 CDCA7 binds to 14-3-3 and is shuttled to the cytoplasm25.  
Several lines of evidence support the notion that Myc and 14-3-3 compete for binding 
to CDCA7. The constitutive 14-3-3 binder DE-CDCA7 binds less Myc than WT CDCA7. Purified 
CDCA7 that is stripped of endogenous interactors will have a population of pT163 CDCA7. 
Addition of Myc to CDCA7 increases the amount of Myc associated with pT163 CDCA7, 
however, addition of Myc and 14-3-3 reduces the amount of Myc bound to pT163 CDCA7. 
The amount of Myc bound to CDCA7 may depend on 14-3-3 and may be determined by the 
phosphorylation status of T163.25  
CDCA7 may be phosphorylated by the Akt kinase. In cells, growth factors bind to 
tyrosine receptor kinases, which then dimerize and autophosphorylate the cytoplasmic 
domains. These phosphorylated residues recruit phosphoinositide-3-kinase (PI3K). PI3K 
then converts phosphatidylinositol-4,5-biphosphase (PIP2) to phosphatidylinositol-3,4,5-
triphosphase (PIP3) at the cell membrane. PIP3 then recruits phosphoinositide -dependent 
kinase 1 (PDK1) which fully activates Akt. Akt then translocates to the nucleus and 
phosphorylates target proteins.31 Inhibition with LY294002, a PI3K inhibitor32 and Akt 
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inhibitor VIII decrease T163 phosphorylation. Gag-Akt, a membrane bound Akt, restores 
pT163 levels in WT CDCA7 but not the T163A mutant. Mouse embryonic fibroblasts (MEFs) 
with deletion of Akt 1 and Akt 2 have no phosphorylated T163 CDCA7. PDGF increases 
phosphorylation of T163 CDCA7 in MEFs only when Akt 1 and Akt 2 are present. Akt also 
phosphorylates WT CDCA7 at T163 but not the T163A mutant in vitro. Taken together, the 
evidence supports the idea that CDCA7 is phosphorylated by Akt at T163.25 
In summary, CDCA7 and Myc interact with one another and may promote apoptosis 
through transcription of apoptotic genes in serum starved environments. CDCA7 is also 
phosphorylated by Akt at T163. Phosphorylation at T163 leads to binding of 14-3-3 at this 
site, which masks CDCA7’s NLS and sequesters it to the cytoplasm. Both Myc and 14-3-3 
compete for binding to pT163. Accordingly, Akt phosphorylation determines the subcellular 
localization of CDCA7 which in turn determines CDCA7’s phenotypic outcome. Refer to 
Figure 1.1 for a schematic representation.  
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Figure 1.1: CDCA7 in relation to Myc, Akt and 14-3-3. The PI3K/Akt pathway is activated by 
mitogenic growth factors. Upon binding to receptor tyrosine kinases (RTKs), the kinases dimerize 
and are activated by autophosphorylation. The active RTKs recruit phosphoinositide-3-kinase (PI3K) 
to the cell membrane which then converts phosphoinositide-4,5-biphosphate (PIP2) to 
phosphoinositide-3,4,5-triphosphate (PIP3). PIP3 recruits phosphoinositide-dependent kinase 1 
(PDK1) to the cell membrane and fully activates Akt kinase. Akt then localizes to the nucleus. CDCA7 
and Myc reside in the nucleus and may interact with one another to potentially drive transcription of 
proapoptotic genes. Akt phosphorylates CDCA7 at threonine (T) 163 which can then be bound by 14-
3-3. After 14-3-3 interaction, CDCA7-Myc interaction is weakened and the proteins dissociate from 
each other. CDCA7 bound to 14-3-3 has its nuclear localization sequence (NLS) concealed. Without 
the NLS, CDCA7 is shuttled to and sequestered in the cytoplasm.  
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CDCA7 Overexpression Promotes Tumorigenesis 
 
 In soft agar colony growth assays, stable expression of CDCA7 in Rat1a fibroblasts 
(Rat1a-CDCA7) has lower transformation induction capabilities in comparison to Rat1a-Myc 
fibroblasts. A point mutation of tryptophan (W) at residue 135 to glutamic acid (E) in the 
Myc Box II domain of Myc cannot transform Rat1a fibroblasts when ectopically expressed. 
However, ectopic expression of W135E Myc in Rat1a-CDCA7 fibroblasts does induce 
transformation.18 The CDCA7 homolog JPO2 also stimulates transformation with W135E 
Myc. JPO2 is overexpressed in the medulloblastoma cell line UW228 as well as 
medulloblastoma tumor patients.22 Deletion of CDCA7’s NLS abolishes its interaction with 
Myc and diminishes transformation in Rat1a-Myc fibroblasts. Knockdown of CDCA7 
decreases the transformation ability of Rat1a-Myc fibroblasts as well.25 So, CDCA7 
expression and CDCA7-Myc interaction may be a requirement for Myc-induced oncogenesis. 
Experiments with microarray analysis found overexpression of CDCA7 in a variety of 
cancers. The complementary DNA (cDNA) of tumor and normal tissue from the same patient 
was probed for CDCA7. Overexpression of CDCA7 was found in lung, stomach, uterus, ovary, 
colon and rectum cancers. Analysis of blood fractions from hematologic cancer patients 
found overexpression of CDCA7 in acute myeloid leukemia (AML) and chronic myeloid 
leukemia (CML). CDCA7 expression was highest in the blast crisis phase of CML. CDCA7 was 
placed under the influence of the H2-K promoter, which is only present in adaptive immune 
cells (B cells and T cells). Transgenic mice expressing this construct had more solid tumors 
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including pancreatic, mesenteric and thymic lymphomas.33 The mRNA expression of CDCA7 
is also elevated in retinoblastoma cells.34 
Patients with esophageal squamous cell carcinoma (ESCC) have amplified regions of 
DNA with the CDCA7 gene. When tumor and normal tissue were compared, elevated levels 
of CDCA7 mRNA expression were found in ESCC patients. Knockdown of CDCA7 in ESCC cells 
has been shown to boost apoptosis, reduce cell growth and led to reductions in the 
phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2). CDCA7 knockdown 
also decreased expression of fibroblast growth factor 21 (FGF21).35 ERK1/2 is part of 
mitogen activated protein (MAP) kinase pathways and following phosphorylation of 
ERK1/2, the kinases activate transcription factors in the nucleus.36 FGF21 promotes glucose 
uptake by stimulating ERK1/2 in adipocytes which leads to expression of the glucose 
transporter 1 gene.37 In pancreatic β-cells, FGF21 stimulates ERK1/2 and the Akt pathway.38 
So, CDCA7 overexpression may promote FGF21 overexpression and lead to overstimulation 
of ERK1/2, which in turn promotes dysregulated cell growth, driving tumorigenesis.35 
Knockdown of CDCA7 in ESCC cells leads to increases in apoptotic gene expression.35 
Cysteine-aspartic proteases (caspases) mediate apoptosis through the extrinsic (receptor-
mediated) and intrinsic (mitochondrial) death pathways. Caspases are present in an inactive 
state (procaspases) and have a prodomain, p20 large subunit and p10 small subunit. 
Procaspases dimerize and remove the prodomain to produce active caspases. Initiator 
caspases respond to apoptotic stimuli and activate through autocatalytic activity. Then 
active initiator caspases cleave executioner caspases which then cleave and degrade cellular 
constituents, leading to cell death.39 Knockdown of CDCA7 also increases mRNA expression 
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of Caspase 10 and Caspase 7.35 Caspase 10 is an initiator caspase only present in humans that 
cleaves caspase-3 and caspase-740 while Caspase 7 is an executioner caspase41. Another gene 
expressed after CDCA7 knockdown is the tumor necrosis factor (TNF)-related apoptosis 
inducing ligand (TRAIL) receptor (R).35 TRAIL-R mediates the extrinsic death pathway by 
binding TRAIL and leading to activation of caspases.42 Thus, overexpression of CDCA7 in 
ESCC cells may drive tumorigenesis by repressing expression of proapoptotic genes.35  
Roles in Development and Stem Cell Maintenance   
 
 The epithelial cells of the thymus play a major role in T cell differentiation and 
maturation. The Forkhead box protein N1 (Foxn1) transcription factor is integral for thymic 
development and Foxn1 null mice are athymic. In zebrafish embryos, knockdown of Foxn1 
leads to deficits in T cell development.  Foxn1 knockdown in zebrafish thymus also reduces 
the levels of CDCA7 mRNA expression. CDCA7 mRNA expression was readily detectable in 
zebrafish and mouse thymic epithelial cells (TECs) and in mouse TEC lines. Knockdown of 
CDCA7 also leads to decreased expression of T cell specific markers in zebrafish embryos. 
When CDCA7 is overexpressed in embryos that have been subjected to Foxn1 knockdown, 
expression of a few T cell markers increases and results in partial rescue from the Foxn1 
knockdown phenotype. Thus, CDCA7 is regulated by Foxn1, is expressed in TECs and its 
expression is partially responsible for T cell development.43  
 Notch signaling occurs in a variety of contexts. In general, when the Notch receptor 
domain is bound by a ligand, several proteolytic cleavages lead to the release of the Notch 
intracellular domain (NICD).44 The NICD then translocates to the nucleus and associates with 
recombination signal binding protein for immunoglobin kappa J (RBPJ), which binds to 
12 
 
target genes of the Notch family.45 The NICD is also bound to the coactivator Mastermind 
(Mam). Together, the Notch-RBPJ-Mam complex drives the transcription of Notch target 
genes. Low intensity interaction between Notch1 and the Jagged ligand (JAG1) is paramount 
to the process of hematopoiesis and hematopoietic stem cell (HSC) specification.44  
Aorta-gonad-mesonephros (AGM) tissue arises during murine embryonic 
development. Target genes of Notch1/RBPJ that are regulated by JAG1 in AGM tissue were 
assayed. Preceding the CDCA7 transcription start site (TTS) are two adjoining RBPJ binding 
sites. ChIP experiments of this region found enrichment of RBPJ, Notch1 and Mam. A 
construct linking these RBPJ binding sites to a luciferase reporter gene found that NICD 
activated the construct and NICD and Mam together increased this basal level of expression. 
Expression of CDCA7 was found in the aortic clusters of AGM tissue where HSCs reside. 
Knockdown of CDCA7 in AGM tissue led to hematopoietic differentiation. Thus, CDCA7 is a 
target gene of the Notch1 signaling pathway, is expressed in HSCs and is involved in 
maintaining the HSC pool during development.46  
Radial glial cells at the luminal side of the neuroepithelial embryonic tissue express 
the paired box 6 (Pax6) transcription factor. This forms a region called the ventricular zone. 
The subventricular zone is located above this region and contains immediate progenitor cells 
(IPCs) which develop from radial glial cells below. After one to two cell divisions, IPCs 
become post mitotic neurons that move into the cortical plate above. IPCs give rise to two-
thirds of all excitatory neurons within the cerebral cortex.  IPCs do not express Pax6 but do 
express the T-box brain 2 (Tbr2) transcription factor while post mitotic neurons do not 
express Tbr2 but do express the T-box brain 1 (Tbr1) transcription factor.47  
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The telencephalon is an embryonic structure that can be subdivided into a dorsal and 
ventral portion. The dorsal telencephalon gives rise to the cerebral cortex and the ventral 
telencephalon gives rise to the basal ganglia.48 Pax6 expression was found to peak within the 
dorsal telencephalon, around the boundary of the lateral cortex and ventral telencephalon. 
This is the region where lateral cortex neuroprogenitors preside. CDCA7 expression in this 
region was relatively low. Inversely, Pax6 expression was lowest in the ventral 
telencephalon whereas CDCA7 expression peaked in this region.  In Pax6 null mice, CDCA7 
expression increased in regions where lateral cortex neuroprogenitors are located.  CDCA7 
was overexpressed in lateral cortex neuroprogenitors via in utero electroporation. CDCA7 
overexpression decreased the number of IPCs produced (cells expressing Tbr2) and 
consequently, few post mitotic neurons (cells expressing Tbr1) reached the cortical plate. 
So, CDCA7 expression maintains a stem-like state in lateral cortex neuroprogenitors and is 
negatively regulated by Pax6 expression, a fundamental requirement for lateral cortical 
development of the cerebrum.49  
ICF Syndrome 
 
 Immunodeficiency, Centromeric instability and Facial anomalies (ICF) syndrome is a 
rare genetic disorder that displays an array of phenotypes. The disorder is typically marked 
by: gastrointestinal and respiratory infections that are lethal, lack of gamma globulin in the 
bloodstream even though B cells are present, facial abnormalities such as a flat nasal bridge 
and centromeric instability.50 Centromeric instability is marked by hypomethylation of 
juxtacentromeric sequences for chromosomes 1, 9 and 16. These sequences occur at 
heterochromatin and are called satellite sequences with GGAAT repeats.51 There are 77 
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verified cases of ICF split into 4 subdivisions. Mutations in DNMT3B, a DNA 
methyltransferase gene, accounts for 56% of all cases, 31% with mutations in the zinc finger 
and BTB binding domain containing 24 (ZBTB24) gene, 6.5% with mutations in the helicase, 
lymphoid specific (HELLS) gene and 6.5% with mutations in the CDCA7 gene.52 
There are five known ICF syndrome patients with mutations in the CDCA7 gene. All 
of these mutations occur in the putative zinc finger DNA binding domain within the C-
terminal of CDCA7. In MEFs, knockdown of CDCA7 led to hypomethylation at 
heterochromatin adjacent to centromeres.50 Deletion of the ZBTB24 gene is embryonically 
lethal in mice. In mouse embryonic stem cells (mESCs), deletion of ZBTB24 decreases CDCA7 
mRNA expression and then overexpression of ZBTB24 reestablishes CDCA7 expression. 
ZBTB24 binds to the CDCA7 promoter and a reduction in CDCA7 mRNA levels is present in 
ICF patients with ZBTB24 mutations.53 Thus, CDCA7 mutations play a role in ICF syndrome, 
its expression is required for methylation of pericentromeric heterochromatin and CDCA7 
may also be responsible for ICF patients with ZBTB24 mutations.50,53  
TPX2 
 
Protein Structure and Function 
 
 Targeting protein for Xenopus centrosomal kinesin-like protein 2 (Xklp2), also 
known as TPX254, is a scaffolding protein which consists of three domains. The N-terminal 
domain interacts with the kinase Aurora A55, the C-terminal domain binds to branching 
networks of microtubules56 and the internal domain contains an NLS. The NLS is 
monopartite and binds to importin alpha.57 TPX2 is located at chromosome 20q.58 TPX2 
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plays an integral role during mitosis and TPX2 null mice are not viable, arresting at the 
morula stage. Embryonic cells of TPX2 null mice are tetraploid and do not contain a bipolar 
spindle, suggesting inability to perform chromosome segregation due to deficits in spindle 
assembly.59 Overexpression of TPX2 also induces polyploidy in somatic cells.60 TPX2 
localizes on spindle poles near centrosomes as well as kinetochores during mitosis.61  
Microtubule Nucleation and Xklp2 
 
Microtubules are structural filaments that are present as alpha (α) and beta (β) 
tubulin subunits. Heterodimerization of the α- and β- subunits form the microtubule 
protofilament and 13 protofilaments form one microtubule. The microtubule tip has GTP 
bound to it (GTP tubulin cap) which stabilizes the microtubule and allows growth. 
Polymerization of microtubule protofilaments or growth begins by subunits joining one 
another, the polymer initially resembles a flattened structure but GTP hydrolysis of 
protofilaments leads to the formation of a lattice structure. Microtubules may also 
depolymerize, a process known as catastrophe. Cycles between growth and catastrophe 
define the structural cycle of microtubules. The ends of microtubules can be defined as plus 
(exposure of β-tubulin) or minus (exposure of α-tubulin). The minus ends of microtubules 
are more stable than plus ends, grow gradually relative to plus ends and loss of the GTP 
tubulin cap does not destabilize it.62  
The nucleation or de novo polymerization of microtubules during mitosis is 
performed by the gamma (γ) tubulin ring complex (γTuRC). During mitosis, microtubule 
nucleation occurs at the microtubule organization center (MTOC) of animal cells, known as 
the centrosome. At the centrosome, γTuRC binds to the minus ends of microtubules and 
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stabilizes this end. The plus ends extend from γTuRC.63 In humans, the protein ninein 
localizes the γTuRC to the centrosome and absence of ninein results in the absence of 
centrosomal γTuRC. Ninein binds to the centriole with its C-terminal domain and the γTuRC 
with its N-terminal domain.64 The model of microtubule nucleation that conforms best to 
evidence present in current scientific literature is the template model.65   
The template model is supported by the crystal structures of the γTuRC. In this model, 
gamma tubulin complex protein (GCP) 1 and GCP2 each bind a γ-tubulin subunit in a 
longitudinal direction, while GCP1 and GCP2 interact with one another laterally. This small 
subunit is known as the gamma tubulin small complex (γTuSC). Six sets of γTuSC are held to 
one another by GCP4, GCP5 and GCP6. This positions 12 γ-tubulin subunits next to one 
another and leaves space for the thirteenth subunit to begin forming the microtubule 
protofilament. It is here that α-tubulin binds (minus end) and initiates nucleation.65 
The nucleation of microtubules may also occur adjacent to already formed 
microtubules during mitosis. In this case, the original microtubule is the mother and 
resulting microtubules are daughters. As expected, reduction of γ-tubulin results in the 
nucleation of few microtubules. Supplementing existing microtubules with the Ras-like 
nuclear protein which is a guanosine triphosphate hydrolase (RanGTPase), and TPX2 results 
in microtubule nucleation, even without the presence of chromosomes and centrosomes.56 
Another component required for branching microtubule networks is the protein complex 
augmin. Augmin is composed of the dim γ-tubulin protein 2 (Dgt2), Dgt3, Dgt4, Dgt5 and 
Dgt6.66 When TPX2 or Augmin is depleted, the time required for microtubule nucleation is 
prolonged and branching of microtubules is ablated. Thus, TPX2 induces microtubule 
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nucleation at preexisting microtubules and is a requirement for formation of microtubule 
branching networks.56    
When daughter microtubules have a branching angle of 90° or less to the mother 
microtubule, they maintain the same orientation as the mother microtubule (same polarity). 
All daughter microtubules initiated by RanGTPase and TPX2 have the same polarity as the 
mother microtubule. Most are nucleated at low branch angles, with the majority having 
angles of less than 30°. The C-terminal region of TPX2 also directly interacts with 
microtubules. Thus, TPX2 along with RanGTPase initiates microtubule branching networks 
where all microtubules share the same polarity and TPX2 directly interacts with 
microtubules.56 
The plus end directed kinesin called Xklp2 was discovered in Xenopus oocytes and 
has centrosomal localization during mitosis. Its motor domain is required for spindle 
assembly and bipolarity, as well as chromosome segregation. When the motor domain of 
Xklp2 is deleted, the spindle poles collapse into each other and only large monopolar 
spindles are present.67 Movement of Xklp2 towards the minus ends of microtubules depends 
on the dynein/dynactin complex and is a requirement for microtubule nucleation during 
mitosis. However, Xklp2 cannot bind to microtubules and move toward the minus ends 
alone. On the other hand, the presence of TPX2 allows for this process. So, TPX2 promotes 
microtubule nucleation by mediating association and movement Xklp2 toward the minus 
ends of microtubules.54 
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RanGTP Regulation  
 
The monopartite NLS of TPX2 binds to importin alpha, and this interaction is 
dependent on residue 284 of TPX2. Mutations of this domain lead to loss of importin alpha 
binding and when these mutants are added to mitotic extracts the resulting phenotype is 
constitutive microtubule assembly.57 Importin alpha (α) associates with importin beta (β) 
and target proteins. The importin α/β complex shuttles cargo proteins across the nuclear 
envelope and in the nucleus RanGTP binds to importin beta, which destabilizes the importin 
α/β complex. The cargo protein is released when importin alpha dissociates from the 
complex and then importin beta remains bound to RanGTP.68 This mode of regulation has 
been demonstrated for TPX2. Thus, TPX2 is imported into the nucleus by interacting with 
importin alpha and freely dissociates in the nucleus by virtue of RanGTP.69   
All phases of the cell cycle consist of a RanGTP gradient. During interphase, 
cytoplasmic RanGTP is absent while high nuclear concentrations of RanGTP are present. 
During mitosis, the regions closest to the cell membrane are devoid of RanGTP while the 
highest concentrations of RanGTP are found near chromatin.70 The subcellular localization 
of RanGTP depends on nuclear transport factor 2 (NTF2). While Ran bound to guanosine 
diphosphate (RanGDP) may move into the nucleus via diffusion, it has been shown to directly 
interact with NTF2 and be imported into the nucleus.71 NTF2 itself shuttles cargo proteins 
by dimerizing and binding to nucleoporins. In particular, the nucleoporin p62, which is an O-
linked glycoprotein is essential for NTF2 nuclear transport.72 The GDP in RanGDP is replaced 
by GTP in the nucleus.73 
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The guanosine exchange factor (GEF) called regulator of chromosome condensation 
1 (RCC1), replaces GDP with GTP on RanGTPase. As RCC1 localizes close to chromatin, 
RanGTP levels are highest at chromatin.73 TPX2 localizes to spindle microtubules near 
kinetochores (chromosomal structure) and near centrosomes during mitosis.61 These 
components are in close proximity to chromatin during spindle assembly.74 Accordingly, 
TPX2 localization during spindle assembly is determined by the RanGTP gradient and in 
turn, the RanGTP gradient is mediated by RCC1 during spindle assembly.73  
TPX2 Deregulation Drives Tumorigenesis  
 
 TPX2 is a well-known oncogene and is overexpressed in several types of cancers. This 
includes but is not limited to colon, liver, ovary, pancreas, mesothelium, cervix, lung, brain, 
salivary gland and oral squamous cell carcinomas.75 As previously mentioned, TPX2 is 
localized to chromosome 20q, a region that is amplified in several cancers and this event is 
associated with progression of colorectal adenomas to invasive carcinomas. The protein 
levels of TPX2 are linked to the DNA copy number of chromosome 20q and knockdown of 
TPX2 expression hinders the invasiveness of colorectal carcinomas.58 As stated, TPX2 is 
involved in microtubule assembly and ultimately chromosome segregation. Improper 
segregation of chromosomes leads to chromosomal/genomic instability, a trademark of 
cancer. In fact, when compared to 10,051 candidate genes, TPX2 had the strongest 
association to chromosome instability.76 So, TPX2 is overexpressed in a variety of cancers, 
plays a role in colorectal carcinoma invasion and is a marker of genomic instability.  
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DNA Damage Response 
 
 The DNA damage response depends on the phosphorylation of histone 2AX (H2AX) 
at the residue serine (S) 139. This phosphorylated version is known as γ-H2AX. When double 
stranded (ds) breaks in DNA occur, the MRN complex is recruited to the region of injury. This 
complex contains nijmegen breakage syndrome protein 1 (NBS1), which then recruits the 
ataxia telangiectasia mutated (ATM) kinase. ATM kinase phosphorylates H2AX at S139, 
generating γ-H2AX.  Recruitment of ATM kinase allows recruitment of mediator of DNA 
damage checkpoint 1 (MDC1). MDC1 will then recruit more ATM kinase. High levels of γ-
H2AX recruit DNA damage response factors which ultimately decide cell fate following the 
dsDNA breaks.77    
The residue serine 634 of TPX2 has been identified as a putative ATM kinase 
phosphorylation site.78 When cells are exposed to ionizing radiation, dsDNA breaks occur 
and activate the DNA damage response. Following ionizing radiation, TPX2 expression was 
found to be correlated with the level of γ-H2AX. Downregulation of TPX2 expression resulted 
in more γ-H2AX while overexpression of TPX2 resulted in less γ-H2AX. TPX2 has been shown 
to interact with NBS1, ATM kinase and MDC1. TPX2 also colocalizes with γ-H2AX, an event 
that occurs only in interphase and not during mitosis. Thus, during interphase, TPX2 
associates with γ-H2AX and other DNA damage response proteins and TPX2 expression 
decreases the levels of γ-H2AX, suggesting an inhibitory role during the DNA damage 
response.79    
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Aurora A Kinase 
 
Protein Expression, Activity and Function 
 
Aurora A kinase belongs to the Aurora family of mitotic kinases and is located on 
chromosome 20q.58 In most tissue, Aurora A localization is restricted to the nucleus.80 
Expression of Aurora A is detected during the S phase, G2 phase and M phase of the cell cycle 
and centrosomal localization of Aurora A occurs during all three of these cell cycle stages.81 
The Aurora A gene contains a cell cycle dependent element (CDE) and a cell cycle homology 
region (CHR) in tandem. Mutation of these regions results in loss of cell cycle dependent 
expression. Expression and activity of Aurora A increases during S phase and peaks in G2 
and M phase.82 So, Aurora A expression and activity peaks during mitotic processes.  
During mitosis, Aurora A localizes to the peripheral regions of centrosomes 
(prophase) and to the spindle microtubules (prometaphase and metaphase). Once spindle 
assembly has been established, expression of Aurora A at the centrosome is not necessary 
for proper cell division to occur. Expression of Aurora A is a fundamental requirement for 
bipolar spindle assembly.81 The catalytic domain of Aurora A determines its localization 
during mitosis. A point mutation of glycine (G) to asparagine (N) at residue 198 of Aurora A 
results in localization to the inner centromere (prometaphase and metaphase) and midzone 
(anaphase). The localization of G198N Aurora A mimics Aurora B localization. In fact, G198N 
Aurora A binds to and phosphorylates the Aurora B targets Survivin and inner centromere 
protein (INCENP).83 So, Aurora A is a nuclear kinase involved in mitotic processes at the 
centrosome and bipolar spindle apparatus and Aurora A localization is dependent on its 
glycine 198 residue.  
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Centrosomin, a centrosomal core constituent and γ-tubulin are recruited by Aurora A 
to the centrosome. Mutations in Aurora A results in the loss of centrosomin and γ-tubulin 
recruitment and consequently, centrosomal maturation does not occur. As a result, 
morphological spindle abnormalities manifest.84 Overexpression of Aurora A leads to 
apparent centrosomal amplification but the kinase activity of Aurora A is not a requirement 
for this phenotype. Overexpression of Aurora A leads to polyploid cell populations (5N-8N). 
This occurs since overexpression leads to failure of cytokinesis. Cytokinesis failure is also 
responsible for multinucleation, as centrosomes accumulate due to failed cell division and 
result in the centrosome amplified phenotype. Over time, the polyploid population increases 
as more and more cells fail to divide. If the cell cycle is arrested in S phase however, this does 
not result and cells are prone to programmed cell death. Interestingly, this phenotype is 
common in p53 null cells as the presence of p53 would arrest the cells in the event of 
polyploidization and/or multinucleation.85 Therefore, Aurora A is involved in centrosomal 
maturation and in the absence of p53, Aurora A overexpression leads to failure of cytokinesis 
which in turn results in centrosome amplification and polyploidy.  
Aurora A null mice are not viable and have been found with missing spindles, 
suggesting inability to form the spindle apparatus. When MEFs that are lacking one Aurora 
A allele were assayed, an approximate increase of 70% was found for polyploid cell 
populations. Inhibition of Aurora A kinase also generated similar findings. Thus, Aurora A is 
integral for development and lack of Aurora A results in polyploidy.86 
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Transcriptional Regulation  
 
The essential heterodimer in the E4 transcription factor 1 (E4TF1) complex consists 
of E4TF1-60 and E4TF1-53, and this heterodimer increases expression of the Aurora A gene. 
E4TF1 was also shown to directly bind to the Aurora A promoter through electromobility 
shift assays (EMSAs).82 Thyroid hormone receptor-associated protein complex 220 kDa 
(TRAP220) has been shown to directly bind to the Aurora A gene via ChIP experiments. 
Expression of TRAP220 increases basal level of Aurora A mRNA expression and 
overexpression of TRAP220 leads to overexpression of Aurora A mRNA.87 ChIP experiments 
have found that both epidermal growth factor receptor (EGFR) and signal transducer and 
activator of transcription 5 (STAT5) bind to the Aurora A promoter. Knockdown of either 
EGFR or STAT5 or both leads to decreases in Aurora A mRNA expression.88 Therefore, 
E4TF1, TRAP220, EGFR and STAT5 directly bind to the Aurora A promoter and 
transcriptionally activate Aurora A gene expression.  
Phosphorylation Targets 
 
Aurora A kinase targets a large array of proteins which are involved in a variety of 
processes, typically during mitosis. For example, Aurora A associates with the large tumor 
suppressor, homolog 2 (Lats2) protein and phosphorylates it at its serine 83 residue. This 
targets Lats2 to the centrosome.89 Other centrosomal proteins phosphorylated by Aurora A 
include but are not limited to aster-associated protein (ASAP)90, nuclear distribution gene E 
homolog (A.nidulans)-like 1 (NDEL1)91 and transforming acidic coiled-coil 3 (TACC3)92. 
Aurora A also phosphorylates a host of transcription factors including p53. Phosphorylation 
of p53 at serine 315 by Aurora A leads to ubiquitination and degradation of p53 by the mouse 
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double minute 2 homolog (mdm2).93 Phosphorylation of p53 at serine 215 by Aurora A 
prevents p53 transactivation by disrupting p53’s DNA binding abilities.94 Other 
transcription factor phosphorylation targets of Aurora A include Ikβα95 and cFos96. Thus, 
Aurora A phosphorylates a variety of target proteins including centrosomal proteins and 
transcription factors.  
Aurora A Kinase Dysregulation Promotes Tumorigenesis  
 
 Amplification of chromosome 20q is associated with a range of cancers and is 
required for promotion of colorectal invasive carcinomas. The DNA copy number of 
chromosome 20q parallels Aurora A protein expression. Inhibition of Aurora A kinase 
expression results in regression of invasive colorectal carcinomas.58 Aurora A 
overexpression is common in colorectal patients and upregulation of Aurora A was detected 
in 41 out of 79 colorectal tumors.97 Deletion of one Aurora A kinase allele in mice increased 
tumor incidence by 3-fold when compared to control mice with both Aurora A kinase alleles. 
Major tumors were found in lung, liver, lymph node and thymus tissue.86 Other cancers with 
Aurora A overexpression include but are not limited to gliomas, cervical cancer, esophageal 
carcinomas, lung cancer and breast cancer.98 Hence, Aurora A is a common oncogene present 
in a plethora of cancer types. 
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TPX2/Aurora A Kinase (TPX2-AurA) Complex 
 
TPX2-AurA Interaction Activates Aurora A Kinase and Promotes Neurite Extension  
 
 Aurora A kinase activation is mediated by interaction of Aurora A with other proteins. 
These interactors include TPX299, human enhancer of filamentation 1 (HEF1)100 and 
Ajuba101. The most defined activator of Aurora A is TPX2. Aurora A autophosphorylates and 
activates itself, the residue in humans is threonine (T) 288.102 Protein phosphatase 2A 
deactivates Aurora A but binding to TPX2 restores kinase activity to Aurora A.99 The crystal 
structure of Aurora A with or without the Aurora A binding domain of TPX2 indicates a 
conformational change in the catalytic domain of Aurora A. The key residue T288 which is 
accessible in Aurora A alone is tucked away upon TPX2 binding.103 Thus, TPX2 interaction 
activates and stabilizes Aurora A kinase. 
 Aurora A kinase and TPX2 play a role in neurite extension in developing mice. Dorsal 
root ganglia from post-natal mice depend on atypical protein kinase C (aPKC), the TPX2-
AurA complex and NDEL1. Phosphorylation of Aurora A at threonine (T) 287 by aPKC 
promotes TPX2-AurA interaction and Aurora A kinase becomes active. This occurs at the 
neurite hillock. Active Aurora A phosphorylates and recruits NDEL1 to the neurite hillock. 
Inhibition of any of these components reduces microtubule nucleation and polymerization 
at the neurite hillock. So, the TPX2-AurA complex promotes neurite extension in developing 
mice.104  
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Microtubule Nucleation Requires the TPX2-AurA Complex 
 
 The RanGTP gradient that regulates localization of TPX2 also regulates Aurora A 
microtubule localization and localization of receptor for hyaluronic-mediated motility 
(RHAMM), the γTuRC and neural precursor cell expressed developmentally downregulated 
protein 1 (NEDD1). The TPX2 in the TPX2-AurA complex associates with RHAMM which 
associates with NEDD1 which associates and recruits the γTuRC.105 NEDD1 is 
phosphorylated by Aurora A at the residue serine (S) 405. Knockdown of NEDD1 or mutation 
of S405 to alanine (A) results in reduction of microtubule nucleation and spindle assembly 
defects. Expression of a constitutively active form of NEDD1 with a mutation at S405 to 
aspartic acid (D) restores microtubule nucleation and compensates for spindle defects.106 
This process was also shown to be RanGTP dependent.105 Therefore, the TPX2-AurA complex 
plays an integral role in microtubule nucleation. A basic overview of the TPX2-Aurora A 
complex and its consequences are outlined in Figure 1.2.  
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Figure 1.2: TPX2/Aurora A Pathway. TPX2 is bound to importin α (Impα) and importin β (Impβ) in 
the cytoplasm. Regulator of chromatin condensation1 (RCC1), a guanine exchange factor, replaces 
GDP with GTP on the Ran GTPase. Once the TPX2-Impα/Impβ complex translocates to the nucleus, 
RanGTP binds Impβ and weakens the Impα/Impβ complex bound to TPX2. Impα and TPX2 
dissociate from each other. Free TPX2 binds to Aurora A kinase and Aurora A autophosphorylates 
and actives itself.  The TPX2/Aurora A complex is localized to microtubules (MT), where Aurora A 
phosphorylates several factors which ultimately leads to MT nucleation. Eventually, the mitotic 
spindle is assembled and chromosome segregation ensues shortly after.  
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Dysregulation of TPX2 and Aurora A Kinase Magnify Oncogenic Progression   
 
As previously stated, protein expression of Aurora A kinase and TPX2 are connected 
to the extent of chromosome 20q amplification. Both TPX2 and Aurora A are positively 
correlated with invasive colorectal carcinoma aggressiveness.58 Aurora A and TPX2 are 
cooperatively overexpressed in a variety of cancers including but not limited to 
gastrointestinal, lung, liver, breast, kidney, ovary, prostate, head-neck and bladder cancers. 
Overexpression of both TPX2 and Aurora A suggests poor prognosis for patients.75 TPX2 and 
Aurora A both induce polyploidy60,86, which leads to chromosomal/genomic instability76, 
one of the hallmarks of cancer. So, TPX2 and Aurora A work synergistically to drive several 
cancer types.  
Biotin Identification (BioID) 
 
A biotin ligase found in Escherichia coli is called bifunctional biotin-[acetylCoA 
carboxylase] holoenzyme synthetase/DNA-binding transcriptional repressor, bio-5'-AMP-
binding (BirA).107 BirA functions by binding to biotin molecules along with adenosine 
triphosphate (ATP), creating an intermediate molecule called biotinyl-adenosine 
monophosphate (bioAMP). When BirA comes into contact with primary amines on amino 
acids (lysine or a resonance structure of arginine), it tags the residue with biotin, releasing 
AMP.  A mutant version of BirA, denoted as BirA*, has a mutation from arginine (R) at residue 
118 to glycine (G). This R118G mutation decreases BirA’s affinity for bioAMP which is then 
prematurely released.108 Primary amines in the vicinity of BirA* will consequently be tagged 
with biotin.109  
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The promiscuous biotin ligase BirA* can be fused to a protein of interest and then be 
stably or transiently expressed in cell lines such as human embryonic kidney (HEK) 293T. 
Addition of biotin to media allows biotin to enter cells and the BirA* fusion protein will then 
tag proximal or interacting proteins with biotin.109 In nature, one of the strongest 
noncovalent interactions is between biotin and streptavidin110, so proteins tagged by the 
BirA* fusion protein can be purified on streptavidin-conjugated agarose beads109. These 
proteins can then be identified by mass spectrometry. This method of identifying potential 
interactors with a BirA* fusion protein is known as biotin identification (BioID).109 
Experiments on two subcomplexes of the nuclear pore complex suggest that a modest 
estimate of the BirA* labelling radius is 10 nanometers.111  
Research Objectives 
 
 The initial goal was to perform BioID to identify novel interactors of CDCA7. Three 
constructs were generated: WT FLAG CDCA7-BirA*, T163A FLAG CDCA7-BirA* and Myc-
BirA*. The protocol for BioID was then optimized for transient transfection of these 
constructs. Once an optimized protocol was established, potential interactors of CDCA7 were 
determined via BioID followed by mass spectrometry. A candidate interaction was then 
verified via coimmunoprecipitation of WT FLAG CDCA7 and the endogenous protein. 
Immunoprecipitation experiments, cell cycle synchronization experiments and 
immunofluorescence experiments were then employed to characterize the interaction.  
 
 
30 
 
Chapter II: Procedures, Protocols and Methodology 
 
Cloning and Related DNA Procedures 
 
Specifics details for cloning are present in the Appendix. Constructs that are not mentioned 
in the Appendix have been cloned for a previous publication25 by other members of the 
Scheid lab. All constructs contain a carbenicillin resistance gene under a bacterial promoter. 
Unless stated otherwise, E. coli cells were grown in Lennox Luria Broth (LB) from Sigma 
Aldrich (Stock Keeping Unit/SKU L3022) supplemented with carbenicillin (100 µg/mL) from 
Sigma Aldrich (SKU C1613). E. coli cells are plated on LB-agar (1.5% w/v; Bacto™ Agar from 
Difco™ & BBL™, Catalog no. 214010) with carbenicillin (100 µg/mL). Cells are NEB® 5-alpha 
(DH5α strain) competent E. coli (subcoloning efficiency) cells (NEB Catalog# C2988). All 
cultures are incubated at 37°C, speed 5 on a VWR S-500 Orbital Shaker.  
Polymerase Chain Reaction (PCR): The Q5 polymerase protocol was performed for all PCR 
reactions. First, volumes of all components were determined and then assembled on ice as 
follows: nuclease-free water (NEB Catalog# B9027), Q5 reaction buffer pack (NEB Catalog# 
B9027), Deoxynucleotide (dNTP) solution mix (NEB Catalog# N0447), reverse and forward 
primers, template DNA, and finally Q5 DNA polymerase (NEB Catalog# M0491). Reverse and 
forward primers are made in a master mix, where the primers have undergone a ten-fold 
dilution. Samples were placed on a thermocycler (Mastercycler® ep from Eppendorf), with 
the following settings: initial denaturation of 98°C for 30 seconds, 35 cycles and a final 
extension at 72°C for 2 minutes. Each cycle consists of denaturation (10 seconds, 98°C), 
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extension (30 seconds/kilo basepair, 50-72°C (based on melting temperature of primers)) 
and extension (25 seconds/kilo basepair, 72°C). PCR products have blunt ends. 
Agarose Gel Electrophoresis: Agarose gels are 1% w/v agarose (BioRad #1613102) and 
made in TAE buffer, pH 8.3 (40 mM Tris, 20 mM acetic acid, 1 mM EDTA). The mixture is 
heated to dissolve the agarose and once it cools, SYBR® Green I nucleic acid gel strain (Sigma-
Aldrich SKU S9430) is added. Gels are cast in an enclosed plastic tray where well-combs are 
added. Agarose gels are then placed in the Sub-Cell GT Cell apparatus from BioRad and TAE 
buffer is added to until the unit reaches full capacity. After samples are loaded, gels are run 
at constant voltage (175 volts) for 60 minutes. Current is provided through a VWR 
AccuPower Model 300 electrophoresis power supply unit.  
Restriction Enzyme Digestion:  Components of the reaction mixture first had their volumes 
established and were then assembled on ice as follows: nuclease-free water, buffer, 
restriction enzymes and finally template DNA. Reaction mixtures are made with the 
recommended enzymes buffers and incubated at the appropriate temperatures for the 
indicated time periods, as mentioned in the manufacturer’s protocol (New England Biolabs 
Inc.). Sequential digests were based on the salt concentrations of the reaction buffers, with 
low concentrations digested first and higher concentrations after.  
Transformation: DH5α E. coli cells (50 µL) are thawed on ice and mixed with 1-5 µL of 
plasmid DNA with gentle agitation. The plasmid-bacteria mix is placed back on ice for 30 
minutes. Cells are placed on the Eppendorf Thermomixer 5436 for 45 seconds at 42°C (heat 
shock) and then placed back on ice for 5 minutes. Then cells are resuspended in SOC 
Outgrowth Medium (NEB Catalog# B9020) and incubated at 37°C for at least one hour. The 
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cells are then resuspended and plated onto an LB-agar plate and placed inverted, overnight 
at 37°C. If colonies appear the next day, plates are stored at -4°C until further use.   
Ligations: The volumes of the reaction mixture components were first determined and then 
the components were assembled on ice as follows: nuclease-free water, T4 DNA ligase buffer 
(NEB Catalog# B0202), vector DNA, insert DNA and finally T4 DNA ligase (NEB Catalog# 
M0202). The reaction mixture is incubated for at least 10 minutes at 25°C. The ligations are 
then transformed. Insert DNA to vector DNA ratios are typically done as 1:1 or 3:1, where 
the size of insert in nucleotides/size of vector in nucleotides multiplied by the amount of 
vector used determines the amount of insert DNA required for 1:1 reactions. A control where 
only vector DNA is used in the ligation is performed to account for the rate of vector DNA re-
annealing to itself. Ideally, this is zero, but if colonies are present, there should be more 
colonies in the actual ligation reactions, in comparison to the vector control.   
Gel Extraction: DNA was purified from agarose gel cut-outs with PureLink™ Quick Gel 
Extraction kit from ThermoFisher Scientific (Catalog no. K210012), according to the 
manufacturer’s protocol.  
Miniprep: After DNA is transformed onto LB-agar plates, a colony was picked and grown 
overnight in 2 mL of media. Cells are pelleted with an Eppendorf 5415D Centrifuge, at 4000 
g, 4°C for 1 minute. The majority of the media is aspirated leaving 50-100 µL. Cells are 
resuspended via VWR Vortex Mixer (2 to 5 seconds). Then 300 µL of TENS lysis buffer (10 
mM Tris-HCl (pH 10.5), 1mm EDTA, 150 mM NaCl, 0.5% SDS w/v) is added and cells are 
vortexed for 2 to 5 seconds. Next, 150 uL of sodium acetate (3 M) is added and lysates are 
vortexed for 2 to 5 seconds. Cell debris and chromosomal DNA is pelleted at 12,000 g, room 
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temperature (RT) for 4 minutes. The supernatant is transferred to a new tube and mixed 
with 900 µL of 95% ethanol. DNA is pelleted at 16,000 g, RT for 10 minutes. The supernatant 
is aspirated, and pelleted DNA is washed twice with 70% ethanol. The DNA pellet is then 
resuspended in TE buffer with 100 µg/mL of RNase A (from the PureLink™ HiPure Plasmid 
Midiprep kit (Catalog no. K210004)).  
Midi/Maxiprep: After DNA is transformed onto LB-agar plates, a colony was picked and 
grown overnight in 100 mL of media. DNA was purified from the overnight cultures of DH5α 
E. coli cells with PureLink™ HiPure Plasmid Midiprep kit (Catalog no. K210004) or 
PureLink™ HiPure Plasmid Filter Maxiprep kit (Catalog no. K210017) or GeneJET Plasmid 
Midiprep kit (Catalog no. K0481), according to the manufacturer’s protocol. All kits are from 
ThermoFisher Scientific.   
Sequence Verification: After DNA is midi/maxiprepped, plasmid DNA is sent for 
sequencing at Bio Basic Inc. or TCGA Facilities (Sick Kids Hospital) along with associated 
sequencing primers for the construct. The sequence reads are compared to the sequence of 
the gene insertion with the Nation Center for Biotechnology Information (NCBI) tool called 
Align Sequences Nucleotide BLAST. BLAST stands for Basic Local Alignment Search Tool.    
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Cell line and Cell Culture Conditions 
 
Cell lines: Human Embryonic Kidney (HEK) 293T cells were obtained from American Type 
Cell Culture Collection and HeLa cells (cervical cancer cells) were a gift from the McDermott 
lab at York University. NIH 3T3 mouse embryonic fibroblast cells were purchased from 
Sigma-Aldrich.  
Cell culture: Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) from 
ThermoFisher Scientific (Catalog no. 11995065) which also contained 10% fetal bovine 
serum (FBS) from ThermoFisher Scientific (Catalog no. 10438026). Media also contained the 
antibiotics streptomycin and penicillin (Catalog no. 15140163) and a derivative of L-
glutamine called GlutaMAX™ (Catalog no. 35050061), both from ThermoFisher Scientific.  
Cells are incubated at 37°C, 5% CO2 in a Sanyo MCO-18AIC UV Double Stack Incubator. 
Passaging: When cells reach 70-80% confluency in a 100 mm dish, media is aspirated and 
then cells are washed once with 10 mL of phosphate-buffered saline (1X) from Corning™ 
(Catalog no. 21-040-CV). Then cells are incubated with 2 mL of Trypsin-EDTA solution from 
Sigma-Aldrich (Stock Keeping Unit/SKU T4299) at 37°C, 5% CO2 for either 1 minute (HEK 
293T cells) or 5 minutes (HeLa cells). Then cells are resuspended with 8 mL of media and 
plated to the desired dilution.  
Long-term storage: One 100 mm dish that is 70-80% confluent is washed once with PBS, 
trypsinized and then cells are collected through centrifugation (100 g, room temperature for 
1 minute). Media is aspirated and then cells are resuspended in 4 mL of storage media. 
Storage media consists of DMEM with 10% dimethyl sulfoxide (DMSO) from BioShop Canada 
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(DMS666), 20% FBS and antibiotics. Next, 1 mL of cells is added to a total of four Corning™ 
externally threaded cryogenic vials from Fisher Scientific (Catalog no. 09-761-71) and stored 
at -80°C until further use.  
Thawing: Cells in a cryogenic vial are placed in a water bath at 37°C until nearly thawed. 
One mL of DMEM is added drop wise to the cells and then cells are plated in a 100 mm dish 
with 8 mL of media. A second 100 mm dish, diluted ten-fold, is plated from the first dish. The 
next day, media is replaced with fresh cell culture media.   
Transfection 
 
Cells are seeded so that plates are 70-80% confluent on the day of transfection. Before 
transfection, all components must be at room temperature (RT). An Axygen® 1.5mL 
MaxyClear Snaplock Microcentrifuge Tube (Corning™ Catalog no. MCT-150-C) is filled with 
200 µL, 1 mL or 2 mL of Opti-MEM™ I reduced serum medium from ThermoFisher 
Scientific (Catalog no. 31985070) for 35 mm, 100 mm or 150 mm dishes, respectively. Next, 
3 µg, 8 µg or 21µg of plasmid DNA are added to the tubes for 35 mm, 100 mm or 150 mm 
dishes, respectively. Then, polyethylenimine (PEI) from Polysciences (cat# 23966-2) is 
added so that the DNA-PEI ratio is 1:3 w/w. The DNA-PEI mixture is vortexed and then 
incubated at RT for 30 minutes. The mixture is then diluted in 800 µL, 3 mL or 6 mL of 
tissue culture media for 35 mm, 100 mm or 150 mm dishes, respectively. Media is 
aspirated from cells and then the DNA-PEI mixture is added to cells, overnight at 37°C, 5% 
CO2. Cells are then subjected to treatments or immediately lysed.  
 
36 
 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Handcast Gels: Gels are cast in 1 mm integrated spacers. The separating gel is cast first, 
followed by the stacking gel with a 10 well-comb. Both the separating and stacking gels are 
made from 30% acrylamide from BioShop Canada (Catalog no. ACR010). The separating gel 
(10% acrylamide) was composed of 375 mM Tris (pH 8.8), 0.1% sodium dodecyl sulfate 
(SDS), 0.1% ammonium persulfate (APS) and the stacking gel (4% acrylamide) was 
composed of 125 mM Tris (pH 6.8), 0.1% SDS, 0.1% APS. APS was added immediately before 
the addition of Tetramethylethylenediamine (TEMED) from Bioshop Canada (Catalog no. 
TEM001). After gels are produced, they are assembled on the MiniPROTEAN® Tetra vertical 
electrophoresis cell from BioRad. The unit is filled to the required volume with running 
buffer, pH 8.6 (25 mM Tris, 192 mM glycine, 0.1% SDS w/v). After samples are loaded, the 
gel is run at constant voltage (175 volts) for 60 minutes. Current is provided through a VWR 
AccuPower Model 300 electrophoresis power supply unit.  
Silver Stain Gels: Gels are cast in Hoefer™ glass plates (1.0 mm) for SE 600 Standard from 
Fisher Scientific (Catalog no. 36-100-3845). The compositions of the separating (12.5% 
acrylamide) and stacking (5% acrylamide) are 375 mM Tris (pH 8.8), 0.1% SDS, 0.1% APS 
and 125 mM Tris (pH 6.8), 0.1% SDS, 0.1% APS, respectively. APS was added immediately 
before the addition of TEMED.  Once gels are produced, they are assembled on the Hoefer™ 
SE 600 vertical electrophoresis unit from Fisher Scientific. The unit is filled to the required 
volume with running buffer, pH 8.6. After samples are loaded, the gel is run at constant 
voltage (50 volts) for 15 hours. Current is provided through a VWR AccuPower Model 300 
electrophoresis power supply unit. 
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Precast Gels: Criterion™ XT Precast 4-12% Bis-Tris gels from BioRad (Catalog no. 
3450124) are assembled into the Criterion™ vertical electrophoresis cell (BioRad). The unit 
is filled with 500 mL of 1X MOPS buffer from BioRad (Catalog no. 1610788). After samples 
are loaded, the gel is run at constant voltage (150 volts) for 90 minutes. Current is provided 
through a VWR AccuPower Model 300 electrophoresis power supply unit.  
Gel Staining 
 
Coomassie Staining: All staining procedures used Coomassie brilliant blue G-250 dye from 
ThermoFisher Scientific (Catalog no. 20279). After electrophoresis, gels are placed in 
containers and completely covered in fixing solution (50% methanol, 10% acetic acid) for 30 
minutes. Gels are then incubated in staining solution (Coomassie brilliant blue G-250 (0.05% 
w/v), 50% methanol, 10% acetic acid) for at least one hour. Finally, gels were destained for 
visualization with destaining solution (5% methanol, 7% acetic acid).  
Silver Staining: Gels were visualized with silver staining with the ProteoSilver™ Silver Stain 
Kit from Sigma-Aldrich (Stock Keeping Unit/SKU PROTSIL1), according to the 
manufacturer’s protocol. 
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Western Blot Procedures 
 
Only Criterion™ XT Precast 4-12% Bis-Tris gels are used for western blotting procedures. 
Transfer: Immobilon-P (PVDF) Membrane (Millipore Sigma Catalog no. IPVH00010) and 
Fisherbrand™ Pure Cellulose Chromatography Paper (transfer paper) from Fisher Scientific 
(Catalog no. 05-714-4) were cut out into rectangle pieces, based on the dimensions of the gel 
to be transferred. The polyvinylidene fluoride (PVDF) membrane is activated by completely 
immersing the membrane in 100% methanol for 10 minutes. The membrane is then soaked 
in transfer buffer, pH 7.2 (bicine 25 mM, Bis-Tris 25 mM, EDTA 1 mM, 10% methanol). Once 
the gel has finished running, the gel and transfer paper are soaked entirely in transfer buffer 
for 10 minutes. The components for transfer are assembled on a Semiphor Semi-dry transfer 
unit from Amersham Pharmacia Biotech. The order of the components are as follows: three 
pieces of transfer paper, PVDF membrane, gel and three more pieces of transfer paper. The 
transfer apparatus is run at constant current (50 milliamps/gel) for 108 minutes. The 
membrane is washed twice with ultrapure water, 5 minutes per wash, before blocking. 
Block: Blocking buffer depends on the type of secondary antibody (fluorescent vs. horse 
radish peroxidase (HRP)). For fluorescent secondary antibodies, membranes are incubated 
in Odyssey® Blocking Buffer (TBS) from LI-COR (Product Number 927-50000) for at least 30 
minutes, prior to incubation with primary antibody. For HRP secondary antibodies, 
membranes are incubated in 5% bovine serum albumin (BSA) for at least 30 minutes, prior 
to primary antibody incubation. BSA is from Sigma-Aldrich (Stock Keeping Unit/SKU 
A2153).  
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Blot: All antibody mixtures are made in tris-buffered saline (TBS), pH 7.4 (50 mM Tris-HCl, 
150 mM NaCl) with 25% blocking buffer. Primary antibodies are added to the antibody 
mixture with 0.1% Tween®-20 from BioShop Canada (Catalog no. TWN510). The primary 
antibodies are incubated with the membrane in a glass tray for one hour at room 
temperature or overnight at 4°C. Next, membranes are washed three times, 5 minutes per 
wash, with 0.1% Tween®-20 in TBS (TBS-T). Secondary antibodies are added to the antibody 
mixture with 0.2% Tween®-20 and 0.01% SDS.  Secondary antibodies are incubated in the 
dark for one hour at room temperature. Membranes are once again washed three times, 5 
minutes per wash, with 0.1% TBS-T before being processed. 
Odyssey: If fluorescent secondary antibodies are used, membranes are scanned on the 
Odyssey® Infrared Imaging System, Model 9120. The system can detect emission 
wavelengths at 700 nm and 800 nm. 
Film: If HRP secondary antibodies are used, membranes are incubated in Pierce™ ECL 
western blotting substrate from ThermoFisher Scientific (Catalog no. 32106) for 5 minutes. 
In a dark room, the membrane, which is secured to an X-ray film cassette, has CL-XPosure™ 
film from Thermofisher Scientific (Catalog no. 34090) exposed to it for various time periods. 
The film is then developed and fixed manually by placing the film in the developing solution 
and then fixing solution, for as long as desired. 
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BioID 
 
RIPA Buffer Protocol: Cells are lysed via sonication on ice in radioimmunoprecipitation 
assay (RIPA) buffer, pH 7.5 (50 mM Tris-HCl, 150 mM NaCl, 1% Triton-X100, 1% sodium 
deoxycholate, 2 mM EDTA, 0.1% SDS). Triton-X100 is from BioShop Canada (Catalog no. 
TRX506). Lysis buffer was supplemented with cOmplete™, EDTA-free Protease Inhibitor 
Cocktail from Sigma-Aldrich (Stock Keeping Unit/SKU 11873580001) and Benzonase from 
Sigma-Aldrich (SKU E1014).  Sonication was performed on Qsonica XL-2000 sonic 
homogenizer, with 3 seconds bursts, followed by 10 second rests, at 5 watts output, until the 
solution became transparent. Cell debris is pelleted through centrifugation (16,100 g, 4°C for 
15 minutes). Soluble lysate is incubated with streptavidin-conjugated agarose beads from 
Millipore Sigma (SKU 69203-3) at 4°C, overnight on a nutator. Next, the lysate is aspirated, 
and beads are washed 5 times with RIPA buffer. After each wash, beads are pelleted through 
centrifugation (400 g, 4°C for 1 minute). After the last wash is removed, cells are eluted in 
SDS sample buffer, pH 6.8 (50 mM Tris-HCl, 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 
12.5 mM EDTA, 0.02% bromophenol blue).  β-mercaptoethanol is from BioShop Canada 
(Catalog no. MER002) and bromophenol blue is from Sigma-Aldrich (SKU B0126). Beads are 
then placed on a heat rack at 100°C for 10 minutes. Samples are stored at -20°C until further 
use. 
Roux Protocol: Cells are lysed with sonication on ice in an SDS-based buffer, pH 7.4 (50 mM 
Tris, 500 mM NaCl, 0.4% SDS, 5 mM EDTA, 1 mM DTT), supplemented with protease 
inhibitor. Then Triton-X100 is added to a final concentration of 2% and cells are sonicated 
on ice. Next, 50 mM Tris, pH 7.4 is added to half the concentration of SDS and prevent 
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precipitation.  Cells are lysed via sonication on ice and cell debris is pelleted through 
centrifugation (16,100 g, 4°C for 15 minutes). Soluble lysate is incubated with streptavidin-
conjugated agarose beads at 4°C, overnight on a nutator. Next, the lysate is aspirated, and 
beads are washed, where each wash occurs for 8 minutes, 25°C on a nutator. After each wash, 
beads are pelleted through centrifugation (400 g, 4°C for 1 minute). Beads are washed twice 
with wash buffer 1 (2% SDS). The lysate is then washed once with wash buffer 2, pH 7.5 (50 
mM Hepes, 150 mM NaCl, 1% Triton-X100, 1% sodium deoxycholate, 1 mM EDTA) and once 
with wash buffer 3, pH 8.1 (10 mM Tris, 250 mM LiCl, 0.5% NP-40, 0.1% deoxycholate, 1 mM 
EDTA). Beads are finally washed twice with wash buffer 4, pH 7.4 (50 mM Tris, 50 mM NaCl). 
After the last wash is removed, cells are eluted in SDS sample buffer saturated in biotin (50 
µM) from Sigma-Aldrich (SKU B5401). Samples are stored at -20°C until further use. 
Mass Spectrometry 
 
Sample preparation, processing and analysis were done by Andrew Macklin, from the Centre 
for Research in Mass Spectrometry at York University.  
Sample Generation: The volumes mentioned in this protocol are valid for one sample. After 
the sample is subjected to the BioID Roux protocol, streptavidin-conjugated beads are 
washed three times in 50 mM ammonium bicarbonate, pH 8.0. Each wash is followed by a 
centrifugation step at 400 g, room temperature (RT) for one minute. After the last wash is 
aspirated, beads are resuspended with 200 µL of 50 mM ammonium bicarbonate, pH 8.0 and 
agitated overnight at 37°C with 1 µg of Promega modified trypsin (Catalog no. V5111). After 
the overnight incubation, 0.5 µg of trypsin is added to the sample for two more hours, at 37°C 
with agitation. Next, beads are pelleted at 400 g, RT for two minutes and the supernatant is 
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shifted to a new tube. Two washes with ultrapure water (150 µL each) are applied to the 
beads and following each wash, beads are pelleted at 400 g, RT for one minute. The washes 
are pooled with the supernatant and the samples are lyophilized in an Eppendorf® Vacufuge 
concentrator at 4°C, overnight. Finally, samples are resuspended in 5% formic acid (10 µL) 
and sent for mass spectrometry. Formic acid is from Sigma-Aldrich (Stock Keeping Unit/SKU 
106526).    
Sample Preparation: Samples are desalted prior to separation via chromatography. 
Samples were bound to C18 ZipTip pipette tips from Millipore Sigma (Catalog no. 
ZTC18S096). Prior to binding samples, ZipTips are cleansed in acetonitrile and washed with 
water. Once the samples are bound, ZipTips are washed in 0.1% formic acid and then eluted 
with 80% acetonitrile. Samples are lyophilized overnight at 4°C and then resuspended in 
0.1% formic acid.  
Processing and Analysis: Samples are first subjected to reversed-phase chromatography 
and the eluted peptides are detected with a 10 µm PicoFrit emitter and scanned with an LTQ 
Orbitrap Elite mass spectrometer. The Proteome Discoverer 1.4 program was used to 
process the obtained data, and then the processed data was compared to the UniPort Data 
base for Homo sapiens in order to identify proteins. Proteins detected at a 10 ppm mass 
threshold, with two or more peptides per match were considered. Identified proteins are 
then ranked based on their score. Experimental and control samples are compared and 
proteins that are common among both are ruled out, along with typical contaminants.  
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Immunoprecipitation (IP) 
 
Cells are lysed via sonication on ice in Nonidet P-40 (NP-40) lysis buffer, pH 7.4 (50 mM Tris-
HCl, 150 mM NaCl, 1% NP-40). NP-40 is from BioShop Canada (Catalog no. NON505). Lysis 
buffer was supplemented with Pierce™ protease and phosphatase inhibitor mini-tablets, 
EDTA free from ThermoFisher Scientific (Catalog no. 88669). Sonication was performed with 
3 seconds bursts, followed by 10 second rests, at 5 watts output, until the solution became 
transparent. Cell debris is pelleted through centrifugation (16,100 g, 4°C for 15 minutes). 
Soluble lysate is incubated with anti-FLAG M2 agarose beads from Sigma-Aldrich (Stock 
Keeping Unit/SKU A2220) at 4°C, overnight on a nutator. Next, the lysate is aspirated, and 
beads are washed 3 times with NP-40 lysis buffer. After each wash, beads are pelleted 
through centrifugation (400 g, 4°C for 1 minute). After the last wash is removed, cells are 
eluted in SDS sample buffer. Beads are then placed on a heat rack at 100°C for 10 minutes. 
Samples are stored at -20°C until further use. 
 
GST Pulldown 
 
Bacterial Culture: BL21-codon plus (DE3) – RIPL E. coli cells were transformed with a GST 
construct, following the same protocol for DH5α E. coli cells (refer to DNA Cloning 
subsection). A colony was picked and grown in 10 mL of LB media with carbenicillin (100 
µg/mL) overnight at 37°C, speed 5 on a VWR S-500 Orbital Shaker. The next day, the 
overnight culture was diluted into 45 mL of LB media with carbenicillin and incubated for 1 
hour. When the optical density (OD) of the culture reached 0.8-1 at 600 nm, 60 µL of lysate 
was taken as a non-induced sample. The culture was then split into two 25 mL cultures and 
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each culture was induced with a different source of isopropyl β-D-1-thioglactopyranoside 
(IPTG) at a final concentration of 1 mM, for 2 hours.  IPTG was either from BioShop Canada 
(Catalog no. IPT002) or Sigma-Aldrich (Stock Keeping Unit/SKU I6758). The cultures were 
then spun down at 4000 g, 4°C for 20 minutes in an Eppendorf Centrifuge 5804. The pellets 
were immediately lysed or stored at -20°C until further use.   
GST Lysate Preparation: Frozen pellets were thawed at room temperature and then 
resuspended in phosphate buffered saline(PBS), pH 7.4 (4.3 mM Na2HPO4, 1.47 mM KH2PO4, 
137 mM NaCl, 2.7 mM KCl, 5 mM DTT). The solution was produced by adding dithiothreitol 
(DTT) to phosphate-buffered saline (1X) at a final concentration of 5 mM. The solution will 
be called 1X PBS. Cells were then lysed with six 10 second pulses at a final watt output of 5, 
alongside 10 second intervening rest periods. Cells were then centrifuged (16,100 g, 4°C for 
15 minutes) and a sample of induced soluble lysate (60 µL) was taken. Next, 100 µL of 
Pierce™ Glutathione agarose beads (GSH beads) were washed three times with water and 
equilibrated with three washes of 1X PBS. Each wash is followed by a centrifugation step 
(400 g, 4°C for one minute).  
GST Purification: The lysate is diluted 4-fold with 1X PBS and then 1 mL of diluted lysate is 
incubated at 4°C with GSH beads, on a nutator for 30 minutes.  After incubation with GSH 
beads, the lysate is aspirated and the beads are subjected to seven washes in 1X PBS. Each 
wash is followed by a centrifugation step (400 g, 4°C for one minute). Then GSH beads are 
resuspended with 1X PBS and 20 µL of the resuspended resin is taken as a sample. The final 
wash is spun down at 400 g, 4°C for one minute and a 60 µL wash sample is taken. Finally, 
GSH beads are incubated in GST elution buffer (20 mM reduced glutathione, 50 mM Tris-HCl, 
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pH 9.0) for 10 minutes, and gently agitated every 2 minutes. Reduced glutathione was from 
Sigma-Aldrich (SKU G4251). The beads are then spun down at 2000 g, 4°C for 5 minutes. A 
sample of the elution (60 µL) was taken. All samples aside from the GSH resin are mixed with 
20 µL of 4X SDS sample buffer. The GSH resin was pelleted (400 g, 4°C for one minute), 1X 
PBS was aspirated and the beads were eluted in 40 µL of 1X SDS sample buffer.  
Synchronization 
 
Double Thymidine Block: Following transfection, cell culture media is replaced with media 
containing 2 mM of thymidine and incubated for 19 hours. Cells are washed once in 
phosphate buffered saline (PBS), pH 7.4 and then incubated in fresh media without 
thymidine for 9 hours. Cells are once again incubated in media containing 2 mM of thymidine 
for 16 hours. Cells are either lysed immediately or released in media without thymidine for 
a desired time period. Thymidine was from Sigma-Aldrich (Stock Keeping Unit/SKU T9250) 
RO3306 G2/M Block: Following transfection, cell culture media is replaced with media 
containing 10 µM of RO3306 and incubated for 18 hours. Cells are either lysed immediately 
or released in media without RO3306 for a desired time period. RO3306 was from Sigma-
Aldrich (SKU SML0569). 
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Cell Cycle Examination  
 
Sample preparation: Following transfection and desired treatments, cells are incubated 
with 2 mL of Trypsin-EDTA solution at 37°C, 5% CO2 for 1 minute, resuspended in 8 mL of 
cell culture media and transferred to a 15 mL conical tube. Cells are spun down at 2000 g, 
room temperature for one minute and resuspended in phosphate buffered saline (PBS), pH 
7.4. Cells spun down at 2000 g, 4°C for one minute, washed with PBS and pelleted again. The 
majority of the PBS is aspirated leaving 100 µL. Then the cells are placed on a vortex, agitated 
gently and 300 µL of 70% ethanol was added to the cells drop wise. After the addition of 
ethanol, cells are stored at -20°C overnight. The next day, cells are washed twice in PBS, each 
wash was followed by a centrifugation step (2000 g, 4°C, 1 minute). Then cells are 
resuspended in PBS and PureLink™ RNase A from ThermoFisher Scientific (Catalog no. 
12091021) was added to a final concentration of 500 µg/mL. Cells were incubated in RNase 
A for 30 minutes at 37°C. Next, propidium iodide was added to cells at a final concentration 
of 40 µg/mL and samples were incubated at 37°C for 30 minutes. Propidium iodide was from 
ThermoFisher Scientific (Catalog no. P1304MP). Samples were then analyzed via flow 
cytometry.  
Flow cytometry: Samples were loaded on a FACSCalibur flow cytometer and visualized 
through CellQuest™ Pro software. A forward scatter vs. side scatter plot determined that 
there was one only population of cells (no contamination from other cell types). A forward 
scatter plot was used to determine the population of singular cells. This channel was gated 
so that only singular cells would be accepted for DNA content analysis. Finally, the DNA 
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content of the cells were analyzed over 50,000 events where one event equates to the 
scanning of a singular cell. The data was further analyzed by Dr. Michael P. Scheid.  
Microscopy 
 
All experiments were performed jointly with Dr. Michael P. Scheid.  
Sample Preparation: Cells are plated on no. 1 glass coverslips and fixed after transfection 
and desired treatments. Next, coverslips are washed in phosphate buffered saline (PBS), pH 
7.4, and after the PBS is aspirated, coverslips are overlaid with 100% methanol at -20°C for 
15 minutes to fix cells. Then, cells are washed twice with PBS. Following fixation, cells are 
blocked with 1% BSA in PBS for 30 minutes followed by incubation with primary antibody 
in 1% BSA PBS for 1-2 hours at room temperature. Slides are washed three times with 1% 
BSA PBS plus 0.025% Tween-20® (PBS-T). Secondary antibody in 1% BSA PBS-T is added 
for 1-2 hours, room temperature, in the dark. Coverslips are washed three times with 1% 
BSA PBS-T, twice with ultrapure water and then dried and mounted on Fisherbrand ™ 
Superfrost™ plus microscope slides from Fisher Scientific (Catalog no. 12-550-15) with 
Prolong™ Gold Antifade mountant with DAPI from ThermoFisher Scientific (Catalog no. 
P36935). Slides are sealed with nail polish and viewed the next day. 
Fluorescence Microscopy: An Olympus microscope was used to visualize cells and images 
are procured with a QImaging 2000R camera linked to the QCapture Pro program.  
Confocal Microscopy: Slides were visualized and images were taken at the Imaging Facility 
at York University.  
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List of Common Reagents 
 
All aqueous acids, bases and alcohols were purchased from the store in Petrie Science and 
Engineering building at York University. 
Table 2.1: Common reagents purchased from BioShop Canada. 
Name 
 
Catalog no. 
Dithiothreitol DTT002 
Ethylenediaminetetraacetic acid (EDTA) EDT002 
Sodium Acetate (NaCH2COOH) SAA304 
Sodium Chloride (NaCl) SOD004 
Sodium Dodecyl Sulfate (SDS) SDS001 
Tris (tris(hydroxymethyl)aminomethane) TRS001 
Tris-hydrochloride (HCl) TRS004 
 
Table 2.2: Common reagents purchased from Sigma-Aldrich. SKU is Stock Keeping Unit. 
Name 
 
SKU 
Ammonium persulfate (APS) A3678 
Bicine B3876 
Bis-Tris B9754 
Glycine G7126 
Sodium deoxycholate D6750 
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Chapter III: Discoveries, Findings and Results 
 
Proximity-dependent Biotin Identification (BioID) 
 
Abridged Version 
The BioID protocol was optimized for the eGFP-3xNLS-BirA* and WT FLAG CDCA7-
BirA* constructs. 
Methods 
Western Blot: Western blots followed the general protocol outlined in Chapter 2. For 
streptavidin pulldowns, biotinylated proteins were detected with IRDye® 680RD 
Streptavidin, which is streptavidin conjugated to an infrared (IR) fluorophore from LI-COR 
(Product Number 925-68079).  FLAG constructs were detected with the mouse monoclonal 
anti-FLAG M2 antibody from Sigma-Aldrich (Stock Keeping Unit/SKU F1804). GFP 
constructs were detected with the GFP (D5.1) XP® rabbit monoclonal antibody from Cell 
Signaling Technology (Product Number 2956).  
Results 
 An optimized BioID protocol tailored to CDCA7 needed to be established before 
determining potential protein interactors of CDCA7 through mass spectrometry. The initial 
objective was to clone the following three constructs: WT FLAG CDCA7-BirA*, T163A FLAG 
CDCA7-BirA* and c-Myc-BirA* (Appendix A). However, experiments were only performed 
on WT FLAG CDCA7-BirA*. A control plasmid to evaluate non-specific targets of biotinylation 
was generated by fusing enhanced green fluorescent protein (eGFP) with BirA*. To mimic 
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the nuclear localization of CDCA7, a coding region containing three tandem copies of the 
SV40 large T antigen nuclear localization sequence (NLS) was incorporated to generate 
eGFP-3xNLS-BirA. The construct eGFP-3xNLS-BirA* will be referred to as GFP-BirA* here 
after.  
Two consecutive BioID protocols were investigated. The initial protocol is based in 
radioimmunoprecipitation assay (RIPA) buffer, which lyses both cytoplasmic and nuclear 
components of cells. Human embryonic kidney (HEK) 293T cells were transiently 
transfected with the GFP-BirA* or the WT FLAG CDCA7-BirA* construct for 24 hours. The 
cells were then left untreated or incubated in DMEM supplemented with 50 µM of biotin for 
24 hours. Cells were then lysed in RIPA buffer supplemented with benzonase and protease 
inhibitor. Benzonase is an endonuclease that cleaves and degrades all forms of DNA and RNA, 
but has no proteolytic activity. The nuclease ensures that biotinylated DNA is not purified. 
The soluble lysate was incubated with streptavidin-conjugated agarose beads overnight on 
a nutator at 4°C. The beads were then washed five times in RIPA buffer prior to elution with 
sodium dodecyl sulphate (SDS) sample buffer.   
Western blots of the lysates confirm that both GFP-BirA* and WT FLAG CDCA7-BirA* 
were expressed (Figure 3.1). Biotinylated proteins were identified by probing blots of 
streptavidin pulldowns with streptavidin IRDye followed by detection on a fluorescence 
scanner (Odyssey). Addition of biotin leads to an increase in the amount of purified 
biotinylated protein when BirA* constructs are expressed. However, the addition of biotin to 
untransfected cells has no effect on the amount of purified biotinylated protein (Figure 3.1). 
Furthermore, upon addition of biotin, the increase in biotinylated protein detected in the 
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streptavidin pulldowns is more evident for the GFP-BirA* control than for WT FLAG CDCA7-
BirA*. There were also too many nonspecific interactors present in the absence of biotin 
(Figure 3.1). As a result, another protocol was considered.   
The next protocol involved the use of an SDS-based lysis buffer and a series of 4 wash 
buffers designed to reduce nonspecific interactions. This protocol was developed by the 
Roux Lab at Sanford Research109 and will be referred to as the BioID Roux protocol. The SDS-
based lysis buffer also lyses both nuclear and cytoplasmic fractions of cells. HEK 293T cells 
were transiently transfected with GFP-BirA* or WT FLAG CDCA7-BirA* for 6 hours. The cells 
were then left untreated or incubated in DMEM supplemented with 50 µM of biotin for 24 
hours. After lysis via sonication, the lysates were incubated with streptavidin-conjugated 
agarose beads, overnight on a nutator at 4°C. The beads were then washed with a series of 
buffers. The first wash buffer utilizes SDS, an ionic detergent, to harshly strip nonspecific 
interactors. The second wash buffer utilizes Triton-X100, a nonionic detergent, to strip 
nonspecific interactors that are still bound to the beads. The third wash buffer includes a 
high concentration of lithium chloride to strip any remaining nonspecific interactors. The 
last wash buffer removes detergents from the sample. Finally, the beads were eluted in SDS 
sample buffer saturated in biotin.  
Streptavidin pulldowns were run on 12.5% polyacrylamide gels and silver stained in 
order to determine the total protein content of the pulldowns. The silver stains showed that 
the addition of biotin substantially increased the amount of protein purified by streptavidin-
conjugated agarose beads. This result was apparent for both GFP-BirA* and WT FLAG 
CDCA7-BirA* (Figure 3.2). Both GFP-BirA* and WT FLAG CDCA7-BirA* are highly visible 
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following the addition of biotin (Figure 3.2). In the absence of biotin, few nonspecific 
interactors were detected (Figure 3.2). Since the BioID Roux protocol resolved the issues 
experienced with the RIPA buffer protocol, it was chosen for all future BioID experiments. 
 In order to increase the yield of protein required for mass spectra identification, an 
experiment was conducted where increasing amounts of lysate was applied to a set amount 
of streptavidin beads. Unlike previous experiments, which were carried out in 100 mm tissue 
culture dishes, the following experiment was carried out in 150 mm dishes. Either GFP-BirA* 
or WT FLAG CDCA7-BirA* was transfected into thirteen 150 mm dishes of HEK 293T cells, 
incubated with DMEM supplemented with 50 µM of biotin and each dish was lysed with 1 
mL of lysis buffer. Then 50 µL of streptavidin-conjugated agarose beads were incubated with 
1 mL, 4 mL or 8 mL of soluble lysate. The remainder of the procedure followed the BioID 
Roux protocol. 
 Streptavidin-conjugated beads were subjected to western blots that were probed 
with streptavidin IRDye or run on 12.5% polyacrylamide gels and silver stained. The western 
blots of the streptavidin pulldowns showed that the amount of biotinylated protein pulled 
down decreased as the volume of soluble lysate increased for both GFP-BirA* and WT FLAG 
CDCA7-BirA* (Figure 3.3). The silver stain also showed a decrease in the amount of protein 
pulled down by streptavidin-conjugated beads as the amount of soluble lysate increased for 
both GFP-BirA* and WT FLAG CDCA7-BirA* (Figure 3.3).  Despite the odd trend, where 
increasing the volume of lysate decreased the amount of purified protein, it became evident 
that one 150 mm plate of HEK 293T cells lysed in 1 mL of lysis buffer pulled down a sufficient 
amount of protein for mass spectrometric analysis.  
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Figure 3.1: BioID of GFP-BirA* and WT FLAG CDCA7-BirA* Constructs (RIPA Buffer Protocol). HEK 
293T cells were left untransfected (control) or transfected for 24 hours with GFP-BirA* or WT FLAG 
CDCA7-BirA*. Following transfection, the medium was replaced with control media or media that 
was supplemented with 50 µM of biotin for 24 hours. Cells were lysed in radioimmunoprecipitation 
assay (RIPA) buffer containing benzonase nuclease and protease inhibitor via sonication. The soluble 
lysate was incubated with streptavidin-conjugated beads overnight. Beads were washed five times 
with RIPA buffer and biotinylated proteins were eluted in SDS sample buffer. Top. Biotinylated 
proteins detected with streptavidin conjugated to an infrared (IR) fluorophore. Addition of biotin 
caused an increase in biotinylated proteins for transfected cells only. Several nonspecific interactors 
are detectable in the untreated lanes.  Middle. Expression of the GFP-BirA* construct detected with a 
GFP antibody. Bottom. Expression of WT FLAG CDCA7-BirA* with a FLAG antibody. 
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Figure 3.2: Silver stain for BioID of GFP-BirA* and WT FLAG CDCA7-BirA* Constructs (Roux 
Protocol). HEK 293T cells were transfected with GFP-BirA* or WT FLAG CDCA7-BirA* for 6 hours. 
Media was then swapped with control media or media containing 50 µM of biotin for 24 hours. Cells 
were lysed via sonication in the BioID lysis buffer with protease inhibitor. The soluble lysate was 
incubated with streptavidin-conjugated beads overnight. Beads were then washed with a series of 4 
wash buffers and proteins were eluted with SDS sample buffer containing 50 µM of biotin. The silver 
stain here exhibits the total protein present in the streptavidin pulldowns. The pulldowns show a 
clear increase in the amount of protein detected when biotin is available in the media. The GFP-BirA* 
(70 kDa) and WT FLAG CDCA7-BirA* (85 kDa) constructs are noticeable following biotin addition 
(arrows indicate molecular weight position of constructs). Only a few non-specific protein 
interactors are visible when biotin is not present in the media.  
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Figure 3.3: Optimization of BioID Roux Protocol. HEK 293T cells in thirteen 150 mm dishes were 
transfected with GFP-BirA* or WT FLAG CDCA7-BirA* and subjected to the BioID Roux Protocol, Cells 
were lysed with 1 mL of BioID lysis buffer per 150 mm dish. Streptavidin-conjugated beads (50 µL) 
were incubated in various volumes of soluble lysate (1 mL, 4 mL and 8 mL, respectively). One 150 
mm dish of transfected HEK 293T cells, lysed in 1 mL of BioID lysis buffer was sufficient to saturate 
50 uL of streptavidin-conjugated beads. Top. Western blot for streptavidin pulldowns of soluble 
lysates at 1 mL, 4 mL and 8 mL, respectively. Biotinylated proteins were detected with streptavidin 
conjugated to an infrared (IR) fluorophore.  Bottom. Silver stain displaying total protein present in 
streptavidin pulldowns of soluble lysates at 1 mL, 4 mL and 8 mL, respectively.  
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Mass Spectrometry 
 
Abridged Version 
 Mass spectrometry results indicate putative interactors of WT CDCA7. The most 
prominent interactor is TPX2.  
Results 
 Once the protocol for BioID was established and fully optimized for CDCA7, mass 
spectrometry samples were generated. Samples were produced from one 150 mm dish of 
transiently transfected HEK 293T cells that were subjected to the BioID Roux protocol. Two 
replicates of GFP-BirA* and WT FLAG CDCA7-BirA* were sent for analysis. Common 
contaminants and nonspecific interactors (proteins found in both the GFP-BirA* and WT 
FLAG CDCA7-BirA* samples) were ruled out. Only proteins present in both replicates of WT 
FLAG CDCA7-BirA* are considered true potential interactors of CDCA7.  
 The results of the mass spectrometry experiment are displayed in Table 3.1. Wild-
type (WT) CDCA7 ranks as the most common interactor of CDCA7. However, due to the 
nature of BioID, it cannot be considered as a potential interactor since WT FLAG CDCA7-
BirA* may simply be biotinylating itself. As a result, the most common interactor following 
WT CDCA7 was considered. Consequently, TPX2 was chosen as the candidate interactor of 
CDCA7 that would be further investigated through coimmunoprecipitation (co-IP) 
experiments.  
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Table 3.1: Mass Spectrometry Results for BioID of WT FLAG CDCA7-BirA*. Following BioID of GFP-
BirA* and WT FLAG CDCA7-BirA*, samples were prepared for mass spectrometry and sent for 
analysis at the Centre for Research in Mass Spectrometry at York University. Mass spectrometric 
experiments and analysis were performed by Andrew Macklin. Protein interactors that were present 
in two replicates and unique to WT FLAG CDCA7-BirA* are shown below. The protein name, 
accession code from the Human UniPort database, number of peptides detected, sequence coverage 
and score are provided. Interactors other than CDCA7 (red) are considered. TPX2 (blue) is the most 
prominent interactor found. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Name Accession Number Peptides Coverage (%) Score 
CDCA7 B4DM13_HUMAN 6 17.5 198.7 
TPX2 Q9ULW0_HUMAN 9 18.1 94.8 
CDCA2 Q69YH5_HUMAN 8 15.3 53.7 
 
SPDL1 Q96EA4_HUMAN 5 19.5 41.5 
CFL1 G3V1A4_HUMAN 3 28.2 35.7 
DLGAP5 Q15398_HUMAN 4 7.01 21.4 
SAP30BP J3KS14_HUMAN 3 42.3 19.2 
SUGT1 A8K7W3_HUMAN 2 11.4 18.3 
ATRX P46100_HUMAN 4 2.8 17.8 
RCC2 Q9P258_HUMAN 2 6.1 6.88 
CDCA8 B4DXT3_HUMAN 2 13.9 5.32 
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WT CDCA7-TPX2 Interaction 
 
Abridged Version 
 Interaction between CDCA7 and TPX2 is verified. The region of interaction is 
suggested to be residues 195-204 of CDCA7. 
Methods 
Western Blot: Western blots followed the general protocol outlined in Chapter 2. For 
streptavidin pulldowns, biotinylated proteins were detected with IRDye® 680RD 
Streptavidin, which is streptavidin conjugated to an infrared (IR) fluorophore from LI-COR 
(Product Number 925-68079). FLAG constructs were detected with the mouse monoclonal 
anti-FLAG M2 antibody from Sigma-Aldrich (Stock Keeping Unit/SKU F1804). Exogenous 
expression of TPX2 was accomplished with a generated TPX2 plasmid construct (Appendix 
B). Endogenous TPX2 and TPX2 constructs were detected with the TPX2 (D2R5C) XP® rabbit 
monoclonal antibody from Cell Signaling Technology (Product Number 12245).  
Results 
 The candidate interactor of CDCA7 that was chosen for further investigation is TPX2. 
In order to validate TPX2 as a bonafide interactor of CDCA7, two experiments were 
performed. The first experiment included transfection of HEK 293T cells with either a FLAG 
vector construct or a WT FLAG CDCA7 construct. Cells were immunoprecipitated on agarose 
beads conjugated to a monoclonal FLAG antibody (anti-FLAG), and were analyzed after 
samples were western blotted. The second experiment involved transfection of HEK 293T 
cells with either GFP-BirA* or WT FLAG CDCA7-BirA* and then cells were subjected to the 
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BioID Roux protocol. SDS-PAGE and western blots were performed on the streptavidin 
pulldowns. 
 Both the immunoprecipitation experiment and BioID experiment were probed with 
a TPX2 antibody (Figure 3.4). TPX2 coimmunoprecipitates with WT FLAG CDCA7 but not the 
vector control and TPX2 is biotinylated by WT FLAG CDCA7-BirA* but not the GFP-BirA* 
control. Thus, TPX2 comes into proximity of and interacts with CDCA7 (Figure 3.4). Purified 
biotinylated proteins and the expression of WT FLAG CDCA7 and WT FLAG CDCA7-BirA* are 
also displayed (Figure 3.4).  
 The next objective was to determine whether certain mutations, substitutions or 
deletions would affect the interaction of TPX2 and CDCA7. HEK 293T cells were transfected 
with WT FLAG CDCA7 or mutations, substitutions and deletions of FLAG CDCA7. Cells were 
lysed, immunoprecipitated and subjected to western blots. Blots were probed for 
endogenous TPX2 with a TPX2 directed antibody. All mutations are point mutations and 
includes T163A CDCA7, which is a loss of function mutation for the AKT phosphorylation site 
within the nuclear localization sequence (NLS) of CDCA7. T234A, another loss of function 
mutation for a potential phosphorylation site on CDCA7, was also investigated. Substitutions 
include DE-CDCA7 and KK-CDCA7. DE-CDCA7 involved the replacement of CDCA7’s NLS with 
a sequence that constitutively binds the 14-3-3 adapter protein. KK-CDCA7 is a mutated 
version of DE-CDCA7 that will not bind to 14-3-3. The constructs Δ156-187 CDCA7 and Δ1-
234 CDCA7 are deletions of the NLS and N-terminal region of CDCA7, respectively.  
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 The results of the experiment show that all FLAG CDCA7 constructs were successfully 
expressed and immunoprecipitated (Figure 3.5). When western blots were probed for 
endogenous TPX2, all the mutations, substitutions and deletions of FLAG CDCA7 bound to 
endogenous TPX2 with the exception of Δ1-234 CDCA7 (Figure 3.5). So, TPX2 does not bind 
within the NLS region of CDCA7 but does bind with the first 234 residues of CDCA7.  
 The subsequent objective was to narrow down the region of interaction of TPX2 and 
CDCA7. FLAG vector, WT FLAG CDCA7 or deletions of FLAG CDCA7 were transfected in HEK 
293T cells, lysed and immunoprecipitated (IP). Western blots were performed on the IPs and 
endogenous TPX2 was detected with a TPX2 antibody. The deletions include the N-terminal 
deletion Δ1-234 CDCA7 and the C-terminal deletion Δ154-371 CDCA7. Deletions of the 
leucine zipper domain (Δ122-137 CDCA7) and the region adjacent to the leucine zipper 
domain and preceding the NLS (Δ138-164 CDCA7) were also examined. Finally, three 
consecutive internal deletions of 8 amino acids (Δ187-194 CDCA7), 10 amino acids (Δ195-
204 CDCA7) and 10 amino acids (Δ205-214 CDCA7) were investigated. The internal 
deletions are adjacent to the NLS.  
 The experiment shows positive results for the expression and purification of all FLAG 
CDCA7 constructs (Figure 3.6). Endogenous TPX2 detected in western blots of the IPs verify 
that Δ1-234 CDCA7 (N-terminal deletion) does not bind to TPX2. The deletions of the leucine 
zipper or its adjacent region still immunoprecipitated TPX2 (Figure 3.6) and therefore TPX2 
does not bind within residues 122-164 of CDCA7. The three internal deletions Δ187-194 
CDCA7, Δ195-204 CDCA7 and Δ205-214 CDCA7 do not bind to TPX2 (Figure 3.6). 
Consequently, TPX2 binds within residues 187-214 of CDCA7. The C-terminal deletion does 
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bind to TPX2, which suggests that TPX2 binds within residues 1-152 of CDCA7 (Figure 3.6). 
However, this large deletion may compromise the three-dimensional (3D) conformation112 
of CDCA7. Whereas the smaller internal deletions are less likely to affect the 3D 
conformation.112 Accordingly, the region adjacent to CDCA7’s NLS (residues 187-214) was 
chosen for further investigation.  
 Finally, the residues 195-204 of CDCA7 were chosen as the potential binding region 
for TPX2. The region contains the sequence PMEEEEEEDK, which contains a string of acidic 
residues (6 residues of glutamic acid (E) and one residue of aspartic acid (D)). The string of 
acidic amino acids may interact with a basic domain on TPX2. To confirm if this region of 
CDCA7 interacts with TPX2, TPX2 was first cloned into a vector where it would be under the 
control of the cytomegalovirus (CMV) promoter (Appendix). Either FLAG vector, WT FLAG 
CDCA7 or Δ195-204 FLAG CDCA7 were cotransfected with TPX2 in HEK 293T cells. Ectopic 
expression of TPX2 was used in order consistently express similar amounts of TPX2 in all 
samples. Cells were lysed and immunoprecipitated. Both lysates and IPs underwent western 
blot procedures.  
 The western blots of the lysates were used as loading controls. Equivalent amounts 
of TPX2 protein were expressed in all samples (Figure 3.7a). The IPs also displayed similar 
expression of WT FLAG CDCA7 and Δ195-204 FLAG CDCA7 (Figure 3.7a). When western 
blots of the IPs were probed for coimmunoprecipitation (co-IP) of the FLAG constructs and 
ectopically expressed TPX2, all constructs tested positive for TPX2 interaction. There is 
significantly more TPX2 bound to WT FLAG CDCA7 in comparison to the vector control, while 
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there is no visible difference in the amount of TPX2 bound to the FLAG vector and Δ195-204 
FLAG CDCA7 (Figure 3.7a). Thus, TPX2 interacts within residues 195-204 of CDCA7. 
 The next objective was to determine if this sequence containing a string of 
acidic amino acids is evolutionarily conserved. Examination of similar regions in other 
species was performed with the Clustal Omega multiple sequence alignment program from 
the European Bioinformatics Institute.  The sequences were obtained from the National 
Center for Biotechnology Information (NCBI) protein database and converted into the FASTA 
format prior to analysis.   
The sequence PMEEEEEEDK from residues 195-204 of human CDCA7 is highly 
conserved in primates with identical sequences present in the west lowland gorilla (Gorilla 
gorilla gorilla), chimpanzee (Pan troglodytes), olive baboon (Papio anubis) and rhesus 
macaque (Macaca mulatta), refer to Figure 3.7b. Similar sequences are present in other 
mammals such as mouse (Mus musculus), rat (Rattus norvegicus), bovine (Bos taurus), horse 
(Equus caballus) and pig (Sus scrofa), refer to Figure 3.7b. The region of interaction seems to 
follow the sequence PXEnDK. Here, P stands for Proline, X (any amino acid, methionine (M) 
in primates and T (threonine) in other mammals), a string of glutamic acid (E) residues, one 
aspartic acid (D) residue at the penultimate residue and finally lysine (K). The degree of 
conservation decreases in avian and ichthyoid (fish-like) species. For chicken (Gallus gallus) 
and zebrafish (Danio rerio), residue X is not present, and the string of acidic amino acids 
immediately follows the proline. For chicken, the final residue is the basic residue arginine 
(R) rather than the basic residue lysine, refer to Figure 3.7b. 
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Figure 3.4: CDCA7 and TPX2 are in proximity to one another and interact. Flag vector (p3xFLAG-
CMV-10), WT FLAG CDCA7, GFP-BirA* or WT FLAG CDCA7-BirA* were transfected in HEK 293T cells. 
Cells transfected with the FLAG vector or WT FLAG CDCA7 constructs were lysed and 
immunoprecipitated (IP) on anti-FLAG conjugated beads. Cells transfected with the BirA* constructs 
were incubated in media with 50 µM of biotin for 24 hours, lysed and then biotinylated proteins were 
purified via streptavidin-conjugated beads. Top. Endogenous TPX2 was detected with anti-TPX2 
immunoblotting. TPX2 is only present in the WT FLAG CDCA7 IP and not in the FLAG vector control. 
TPX2 is only present in the WT FLAG CDCA7-BirA* streptavidin pulldown and not in the GFP-BirA* 
control.  Middle. Biotinylated proteins were identified with a streptavidin-conjugated infrared (IR) 
fluorophore. Bottom. Ectopically expressed FLAG constructs were identified with anti-FLAG 
immunoblotting. 
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Figure 3.5: TPX2 interacts within the first 234 residues of CDCA7. WT FLAG CDCA7 or the indicated 
point mutations, substitutions or deletions were transfected in HEK 293T cells, lysed and 
immunoprecipitated (IP) on anti-FLAG conjugated beads. Roles of mutations, substitutions or 
deletions: T163A (mutation of AKT phosphorylation site), ∆156-187 (nuclear localization sequence), 
DE (constitutive 14-3-3 interactor), KK (constitutive 14-3-3 non-binder) and ∆1-234 (N-terminal 
deletion).  Top. Endogenous TPX2 was detected with anti-TPX2 immunoblotting. TPX2 is absent in 
the ∆1-234 FLAG CDCA7 IP. Bottom. Ectopically expressed FLAG constructs were identified with anti-
FLAG immunoblotting. 
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Figure 3.6: TPX2 interacts within residues 187-214 of CDCA7. WT FLAG CDCA7 or the indicated 
deletions were transfected in HEK 293T cells, lysed and immunoprecipitated (IP) on anti-FLAG 
conjugated beads. Roles of deletions:  ∆1-234 (N-terminal deletion), ∆154-371 (C-terminal deletion), 
∆122-137 (Leucine zipper domain), ∆138-164 (region between leucine zipper domain and nuclear 
localization sequence/NLS), ∆187-194, ∆195-204 and ∆205-214 (regions adjacent NLS). Top. 
Endogenous TPX2 was detected with anti-TPX2 immunoblotting. TPX2 is absent in the ∆187-194 
FLAG CDCA7, ∆195-204 FLAG CDCA7 and ∆205-214 FLAG CDCA7 IPs. Bottom. Ectopically expressed 
FLAG constructs were identified with anti-FLAG immunoblotting. 
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Figure 3.7: TPX2 interacts within residues 195-204 of CDCA7. A) Flag vector (p3xFLAG-CMV-10), 
WT FLAG CDCA7 or Δ195-204 FLAG CDCA7 were co-transfected with TPX2 into HEK 293T cells, lysed 
and immunoprecipitated (IP) on anti-FLAG conjugated beads. Top. Endogenous TPX2 was detected 
with anti-TPX2 immunoblotting. The amount of TPX2 in the vector IP is compared with the amount 
of TPX2 present in either WT or Δ195-204 FLAG CDCA7 IP. There is a significant difference in the 
amount of TPX2 when the vector control is compared to WT FLAG CDCA7, but there is no difference 
when the vector control is compared to Δ195-204 FLAG CDCA7. Middle. Ectopically expressed FLAG 
constructs were identified with anti-FLAG immunoblotting. Bottom. The amount of TPX2 in the 
soluble lysates were used as a loading control. B) The residues 195-204 in human CDCA7 contains 
amino acids PMEEEEEEDK. This region containing a string of acidic amino acids, mainly glutamic acid 
(E) is evolutionarily conserved (black). The region is highly conserved in primates and is also 
conserved between mammals. Asterisks (*) denote identical amino acid matches while colons (:) 
indicate similar matches.  
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Zebrafish   208 SRSLVDGPPSPPPED-------EEEDKYSLVRRSRGYEDVDEEEKEPRRRSYNSSLTIPH 260 
Chicken     224 SRSLIEGPPTPLPEE-------EDDDRYLLVRRRKMSGEDLEHDAQTPRRGHRGAMALPH 276 
Mouse       190 SRSRILGSLGALPTEEEEEEEEEEEDKYMLVRQRKSMDSYMNDDDVPRSRRP-GSMTLPH 248 
Rat         186 SRSRILGSLGALPTEEEED-EEEEEDKYMLVRRRKSVDGYMNDDDVSRSRRP-GSMTLPH 243 
Baboon      183 SRSRILGSLDALPMEEE-----EEEDKYMLVRKRKTMDGYMNEDDLPRSRRSRSSMTLPH 237 
Macaque     183 SRSRILGSLDALPMEEE-----EEEDKYMLVRKRKTMDGYMNEDDLPRSRRSRSSMTLPH 237 
Gorilla     183 SRSRILRSLDALPMEEE-----EEEDKYMLVRKRKTMDGYMNEDDLPRSRRSRSSVTLPH 237 
Human       183 SRSRILGSLDALPMEEE-----EEEDKYMLVRKRKTVDGYMNEDDLPRSRRSRSSVTLPH 237 
Chimpanzee  183 SRSRILGSLDALPMEEE-----EEEDKYMLVRKRKTMDGYMNEDDLPRSRRSRSSVTLPH 237 
Horse       290 SRSRILGSLSALPTEEEEE-EEEEDDKYVLVRKRKAVDGYMNGDDVPRGRRP-GSMTLPH 348 
Cow         183 SRSRVLGSLSALPTEEEEE-EEEEEDKYMLVRKRKSMVGYMNEDDMPRSRRP-GPMTLPH 240 
Pig         183 SRSRVLGSLGALPTEEEEE--EEEEDKYMLVRKRKPTDGYLNEDDMPRSRRP-GSMTLPH 239 
                *** :       * :       *::*:* ***: :      : :     *   . :::** 
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Phosphorylation of CDCA7 by Aurora A Kinase 
 
Abridged Version 
 Residue T163 of CDCA7 matches the Aurora A kinase phosphorylation consensus 
motif. Inhibition of Aurora A kinase decreases phosphorylation of T163 along with CDCA7-
14-3-3β interaction.  
Methods 
Western Blot: Western blots followed the general protocol outlined in Chapter 2. FLAG 
constructs were detected with the mouse monoclonal anti-FLAG M2 antibody from Sigma-
Aldrich (Stock Keeping Unit/SKU F1804). Phospho-T163 (pT163) CDCA7 was detected with 
a pT163 CDCA7 polyclonal rabbit antibody, produced via GenScript Corporation (CA). A 
rabbit polyclonal antibody of 14-3-3β from Santa Cruz (catalog Number sc-628) was used to 
detect endogenous 14-3-3β. Aurora A Inhibitor I is from Sigma-Aldrich (SKU SML0882) and 
MLN8237 is from APExBIO (Catalog no. A4110). 
Results 
 The previous section verified the interaction between CDCA7 and TPX2. As 
mentioned above, TPX2 is a well-known interactor and regulator of Aurora A kinase. Based 
on sequence analysis of CDCA7 performed on the phosphorylation motif application Scansite 
3.0, the residue T163, which was previously shown to be phosphorylated by Akt, was also a 
very high match for the consensus phosphorylation site of Aurora A.  The consensus motif of 
Aurora A is [R/K/N]-R-X-S/T-B, where [R/K/N] indicates that the first residue is either 
arginine (R), lysine (K) or asparagine (N). The second residue is arginine (R), followed by X 
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(any amino acid), serine or threonine (S/T) and finally B (any hydrophobic amino acid other 
than proline)113, refer to Figure 3.8a. Residues 160 to 164 within the nuclear localization 
sequence (NLS) of CDCA7 perfectly match the Aurora A consensus motif, with the sequence 
R-R-R-T-F (Figure 3.8a). Accordingly, experiments investigating this region were conducted.  
 To determine whether Aurora A kinase phosphorylates CDCA7 at threonine 163, 
experiments using inhibitors of Aurora A kinase were conducted. First, an inhibitor designed 
by Sigma Aldrich, Aurora A Inhibitor I, was used to determine if inhibition of Aurora A kinase 
affects the level of phospho-T163 (pT163). HEK 293T cells were transfected with WT FLAG 
CDCA7 and then cells were left untreated or were incubated with 1 µM of Aurora A Inhibitor 
I for a set period of time (3, 6, 9, 12 or 24 hours). Cells were then lysed, immunoprecipitated 
(IP) on anti-FLAG conjugated beads and the IPs were subjected to western blotting. The same 
experiment was performed with 5 µM of Aurora A Inhibitor I. Cells were not treated with 
inhibitor for 24 hours at the 5 µM concentration, but a control was included where cells were 
transfected with FLAG vector and left untreated.  
 The expression of WT FLAG CDCA7 was confirmed by probing the IPs with an anti-
FLAG antibody. All samples transfected with WT FLAG CDCA7 had similar levels of 
expression (Figure 3.8b and Figure 3.8c). The IPs were also probed for pT163 CDCA7 and all 
samples expressing WT FLAG CDCA7 tested positive of T163 phosphorylation (Figure 3.8b 
and Figure 3.8c). The ratio of pT163 CDCA7 to total WT FLAG CDCA7 for each sample was 
determined. The ratio of the untreated WT FLAG CDCA7 sample was set to one-fold and all 
other ratios were divided by the untreated ratio to determine their fold. After three hours of 
incubation with Aurora A Inhibitor I at 1 µM, the pT163 CDCA7 levels had decreased by more 
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than 50% when compared to the untreated sample (Figure 3.8b). A greater than 80% 
decrease in the pT163 level occurred following incubation of cells with Aurora A Inhibitor I 
at 5 µM, in comparison to the untreated sample (Figure 3.8c). Thus, inhibition of Aurora A 
kinase decreases the amount of phosphorylation for T163 CDCA7. 
 The concentrations of Aurora A Inhibitor I were relatively high (µM scale) for 
detectable decreases in pT163 CDCA7 levels. These high concentrations may be 
nonspecifically inhibiting other kinases, which in turn leads to the detected decrease in 
pT163 CDCA7 levels. In order to confirm that Aurora A specifically affects the 
phosphorylation status of T163 CDCA7, the inhibitor MLN8237 was used. This inhibitor was 
described in the literature to exclusively inhibit Aurora A kinase.98 HEK 293T cells were 
transfected with FLAG vector and left untreated. Cells were also transfected with WT FLAG 
CDCA7, left untreated or treated with MLN8237 over a range of concentrations (20 nM, 100 
nM, 200 nM or 500 nM) or treated with Aurora A Inhibitor I at 5 µM. Treatment with inhibitor 
was set to one hour. Then cells were lysed, immunoprecipitated and both lysates and IPs 
underwent western blotting procedures.  
 Lysates were probed with an anti-FLAG antibody in order to determine WT FLAG 
CDCA7 expression. All samples that were transfected with WT FLAG CDCA7 successfully 
expressed the construct at comparable levels (Figure 3.9). Lysates were also probed for 
pT163 CDCA7, which was also positive when WT FLAG CDCA7 was expressed (Figure 3.9). 
IPs were probed for 14-3-3β and was positive for samples where WT FLAG CDCA7 was 
expressed (Figure 3.9). Folds were determined in the same manner as the Aurora A Inhibitor 
I experiments performed in Figure 3.8b and 3.8c. Decreases of approximately 50% and 70% 
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occurred for the 14-3-3β-CDCA7 interaction following treatment with MLN8237 (100 nM) 
and Aurora A Inhibitor I (5 µM), respectively (Figure 3.9). When cells were incubated with 
100 nM of MLN8237 for one hour, a greater than 40% drop in the pT163 level occurred, as 
compared to the untreated sample (Figure 3.9). Higher concentrations of MLN8237 (200 nM 
and 500 nM) did not have a similar effect, however. A similar decrease (50%) in the pT163 
CDCA7 level took place after cells were incubated with Aurora A Inhibitor I for 1 hour at 5 
µM (Figure 3.9). Low concentrations of an Aurora A specific inhibitor (MLN8237) produced 
similar drops in the pT163 CDCA7 level as high concentrations of Aurora A Inhibitor I. This 
provides strong support for the notion that CDCA7 is phosphorylated by Aurora A kinase at 
residue T163.  
 The next objective would be to verify if CDCA7 can be phosphorylated by Aurora A 
kinase in vitro. First, GST-WT FLAG CDCA7 and a GST control were subjected to purification 
on GSH beads. Non-induced lystes and induced lysates from two different sources of IPTG 
were obtained. Comparison between noninduced and induced lysates was done to verify 
expression of the GST constructs. The wash sample is a control which will indicate whether 
a GST construct is/is not eluted prior to the elution step. The resin is a control that verifies if 
a GST construct bound to reduced glutathione (GSH) beads to begin with and the elution 
indicates whether a GST construct has been purified off the GSH beads. Samples were 
subjected to SDS-PAGE and proteins were detected with Coomassie stain. While the GST 
control construct was successfully purified, GST-WT FLAG CDCA7 could not be expressed 
and consequently lead to failed purification (Figure 3.10). As a result, in vitro kinase assays 
with GST-WT FLAG CDCA7 and Aurora A kinase were not possible.   
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Figure 3.8: Phosphorylation of T163 CDCA7 via Aurora A Kinase. All experiments were done in HEK 
293T cells. A) Consensus motif (CM) for Aurora A is compared to residues 160-164 of CDCA7. This 
region of CDCA7 matches the CM of Aurora A completely. B) Following transfection of WT FLAG 
CDCA7, cells are left untreated or subjected to Aurora A Inhibitor I (1 µM) for the indicated time (in 
hours), lysed and immunoprecipitated (IP) on anti-FLAG conjugated beads. Top. Phosphorylation of 
T163 (pT163) is detected with anti-pT163 CDCA7 immunoblotting. Bottom. Ectopically expressed 
FLAG constructs were identified with anti-FLAG immunoblotting. The ratio of pT163 CDCA7/FLAG 
CDCA7 is provided and this ratio in untreated cells in set to one-fold. Over 3 hours there is a greater 
than 50% drop in pT163 levels. C) Same as in B expect Aurora A inhibitor I concentration is 5 µM. 
Flag vector (p3xFLAG-CMV-10) is added as an additional control. Over 3 hours there is a greater than 
80% drop in pT163 levels. Abbreviations. AurA is Aurora A Kinase.  
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Figure 3.9: Aurora A Kinase specifically phosphorylates T163 CDCA7. Following transfection with 
either Flag vector (p3xFLAG-CMV-10) or WT FLAG CDCA7, HEK 293T cells are left untreated or 
incubated in the indicated concentrations (nM) of MLN8237 or in 5 µM of Aurora A Inhibitor I for 1 
hour. Cells are then lysed and immunoprecipitated (IP) on anti-FLAG conjugated beads. Top. 
Phosphorylation of T163 (pT163) is detected with anti-pT163 CDCA7 immunoblotting. Middle. 
Ectopically expressed FLAG constructs were identified with anti-FLAG immunoblotting. Bottom. 
Endogenous 14-3-3β is detected with anti-14-3-3β immunoblotting. The ratio of pT163 CDCA7/FLAG 
CDCA7 is provided and this ratio in untreated cells is set to one-fold. The ratio of 14-3-3β/FLAG 
CDCA7 is provided and this ratio in untreated cells in set to one-fold. Over the span of 1 hour, there 
is a 50% drop in pT163 levels with Aurora A Inhibitor I (5 µM), whereas a comparable drop of 40% 
in pT163 levels occurs with 100 nM of MLN8237. Abbreviations. AurA Inh I is Aurora A Inhibitor I. 
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Figure 3.10: Purification of GST-WT FLAG CDCA7 (Negative Result). Two colonies of either GST or 
GST-WT FLAG CDCA7 (GWC) in BL21-codon plus (DE3) – RIPL E. coli cells were grown in LB 
supplemented with carbenicillin. Cells were induced with two different sources of isopropyl β-D-1-
thiogalactopyranoside (ITPG) for 3 hours, pelleted, lysed via sonication and incubated on reduced 
glutathione (GSH) beads. The beads were then washed seven times in wash buffer (1X PBS, pH 7.4). 
Prior to elution, a sample of the resin was stored. This sample verifies that the GST construct bound 
to the resin in the first place. Finally, the beads were eluted in 20 mM of GSH in Tris-HCl, pH 9.0. The 
order of lanes are as follows: non-induced lysate, induced lysates from IPTG sources 1 and 2, 
respectively, wash, resin and elution. Top. The GST construct (26 kDa) was purified following elution. 
Bottom. The GWC construct was not expressed since a prominent band of ~76 kDa is not present in 
the induced lysates. Failure to purify GWC made in vitro kinase assays with GWC and Aurora A kinase 
impossible.  
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Cell Cycle Modulation of CDCA7 and CDCA7 Interactors 
 
Abridged Version 
 Cells are synchronized to the G1/S boundary and then released. The interaction 
between 14-3-3β and WT CDCA7 and the phosphorylation status of residue T163 for CDCA7 
coincide with one another. CDCA7-TPX2 interaction continually decreases over the cell cycle. 
Methods 
Western Blot: Western blots followed the general protocol outlined in Chapter 2. FLAG 
constructs were detected with the mouse monoclonal anti-FLAG M2 antibody from Sigma-
Aldrich (Stock Keeping Unit/SKU F1804). Phospho-T163 (pT163) CDCA7 was detected with 
a pT163 CDCA7 polyclonal rabbit antibody, produced via GenScript Corporation (CA). A 
rabbit polyclonal antibody of 14-3-3β from Santa Cruz (catalog Number sc-628) was used to 
detect endogenous 14-3-3β. Endogenous TPX2 was detected with the TPX2 (D2R5C) XP® 
rabbit monoclonal antibody from Cell Signaling Technology (Product Number 12245). 
Results 
 The previous two sections confirmed interaction of CDCA7 and TPX2, and highlighted 
CDCA7 as a potential target for Aurora A phosphorylation. The changes in the degree of 
interaction for CDCA7-14-3-3β or CDCA7-TPX2 and the changes in the phosphorylation 
status of T163 CDCA7, over the cell cycle, were investigated. HEK 293T cells were transfected 
with FLAG vector or WT FLAG CDCA7 and synchronized to the G1/S checkpoint via double 
thymidine block114. Cells were either stained with propidium iodide (PI) and analyzed 
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following flow cytometry or cells were lysed, immunoprecipitated (IP) and the IPs were 
subjected to western blotting.  
 Data from synchronized cells subjected to flow cytometry was analyzed and 
graphically represented by Dr. Michael P. Scheid.  Following synchronization, cells were 
released over various timepoints (0, 2, 4, 6, 8, 10, 12, 14 or 16 hours) prior to being 
harvested. The cell cycle profile of these timepoints are displayed in Figure 3.11. The y-axis 
of each graph represents the number of cells and the x-axis represents the DNA content. 
Units are arbitrary for both axes and for the x-axis, 50 units denotes cells in G1, 100 units 
denotes cells in G2, and any cells within 50-100 are in S phase (Figure 3.11). Prior to release 
(0 hours), the majority of cells are at the G1/S boundary (Figure 3.11). After 4 hours of 
release, a population of the cells have moved into the G2 phase and by 8 hours of release, 
cells have again moved to G1 or S phase (Figure 3.11). This graphical representation shows 
that cells subjected to double thymidine block are synchronized and remain synchronized 
for the 16 hours of release displayed.   
 The expression and purification of WT FLAG CDCA7 was confirmed by probing IPs 
with an anti-FLAG antibody. When WT FLAG CDCA7 is transfected, the construct can be 
detected, and all samples of WT FLAG CDCA7 have similar levels of expression (Figure 3.12). 
The IPs were also probed for phospho-T163 (pT163) CDCA7, endogenous 14-3-3β or 
endogenous TPX2. The ratios of either pT163 CDCA7, endogenous 14-3-3β or endogenous 
TPX2 and total WT FLAG CDCA7 were determined. The ratio at zero hours of release was 
normalized to one-fold and the other ratios were divided by this ratio to determine their fold. 
Both pT163 CDCA7 and 14-3-3β levels decrease after the zero hour release point and are at 
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their lowest after 8 hours of release. Then both pT163 CDCA7 and 14-3-3β levels undergo a 
recovery period between 10 hours and 16 hours of release, where levels rise close to their 
original folds (Figure 3.12). TPX2 levels on the other hand continually decrease over time 
(Figure 3.12).  
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Figure 3.11: Cell cycle profile of synchronized HEK 293T cells obtained from flow cytometry. 
Following double thymidine block, cells are synced to the G1/S checkpoint. The cells are then 
released for the indicated durations.  DNA was stained with propidium iodide. The progression of 
cells through the cell cycle is clearly visible over this 16-hour interval. The x-axis denotes DNA 
content, cells at 50 units are in G1, cells at 100 units are in G2 and cells between 50 and 100 units are 
in S phase.  The y-axis denotes the number of cells. Units are arbitrary.  
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Figure 3.12: TPX2, pT163 CDCA7 and 14-3-3β protein levels vary throughout the cell cycle. HEK 
293T cells were transfected with Flag vector (p3xFLAG-CMV-10) or WT FLAG CDCA7, subjected to 
thymidine double block synchronization, and released at indicated time points (in hours). Cells were 
lysed and immunoprecipitated (IP) on anti-FLAG conjugated beads. Top. Phosphorylation of T163 
(pT163) is detected with anti-pT163 CDCA7 immunoblotting. Second row. Endogenous 14-3-3β is 
detected with anti-14-3-3β immunoblotting. Third row. Endogenous TPX2 is detected with anti-TPX2 
immunoblotting. Bottom. Ectopically expressed FLAG constructs were identified with anti-FLAG 
immunoblotting. Ratio of pT163 CDCA7/FLAG CDCA7, 14-3-3β/FLAG CDCA7 and TPX2/FLAG CDCA7 
is provided and these ratios at zero hours of release are set to one-fold. Both pT163 and 14-3-3β 
levels decrease and then recover over the 16 hour interval whereas TPX2 levels continuously 
decrease over the 16 hour interval. 
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CDCA7 and Mitosis 
 
Abridged Version 
 During mitosis CDCA7 localizes to the centrosomes where it is phosphorylated at 
residue threonine (T) 163. CDCA7 also colocalizes with TPX2 during mitosis and 
phosphorylation of residue T163 CDCA7 increases throughout mitosis. 
Methods 
Western Blot: Western blots followed the general protocol outlined in Chapter 2. FLAG 
constructs were detected with the mouse monoclonal anti-FLAG M2 antibody from Sigma-
Aldrich (Stock Keeping Unit/SKU F1804). Phospho-T163 (pT163) CDCA7 was detected with 
a pT163 CDCA7 polyclonal rabbit antibody, produced via GenScript Corporation (CA). 
Endogenous CDCA7 was detected with a monoclonal rabbit antibody from Sigma-Aldrich 
(SKU HPA005565) 
Results 
 The previous sections have demonstrated that CDCA7 interacts with TPX2 and is a 
candidate substrate for Aurora A phosphorylation. Both TPX2 and Aurora A kinase play 
important roles in spindle assembly and regulation as well as centrosomal regulation, during 
mitosis.74, 81 Accordingly, it is expected that CDCA7 may also play a role during the mitotic 
phase of the cell cycle. A series of immunofluorescence experiments were performed to 
examine CDCA7 within the context of mitosis. All microscopy experiments were performed 
jointly with Dr. Michael P. Scheid.  
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 The first experiment was done in asynchronous cells. HEK 293T cells were transiently 
transfected with WT FLAG CDCA7. Ectopically expressed CDCA7 was found in prophase 
(nuclear envelope disappears and spindles begin to form) and metaphase (chromosomes 
line up along the metaphase plate), refer to Figure 3.13. During prophase, WT FLAG CDCA7 
and its phosphorylated version phospho-T163 (pT163) CDCA7 were detected and appear as 
spherical, bright foci. There are several foci present during prophase (Figure 3.13). During 
metaphase, WT FLAG CDCA7 is found as two concentrated regions located adjacent to the 
DNA lined up at the metaphase plate (Figure 3.13). The regions of localization for WT FLAG 
CDCA7 during metaphase resemble that of centrosomes.  
 For all subsequent experiments within this section, cells are synchronized with 
compound RO3306, a Cyclin-dependent kinase 1 (CDK1) inhibitor that synchronizes cells to 
the G2/M checkpoint115.  This increases the number of cells captured in the mitotic phase. 
The previous experiments have indicated that ectopically expressed CDCA7 localizes to 
regions in the same manner as centrosomes.  The next objective was to determine if 
endogenous CDCA7 does colocalize with known centrosomal markers. Gamma (γ) tubulin is 
a known marker of centrosomes and is used to determine if CDCA7 localizes to the 
centrosomes. HeLa cells are synchronized with RO3306, released for 40 minutes and 
prepared for immunofluorescence. Cells are probed for endogenous CDCA7 and γ-tubulin 
and imaged after confocal microscopy. Cells in metaphase/anaphase (sister chromatids have 
just begun to pull apart from the metaphase plate) show that endogenous CDCA7 and 
endogenous γ-tubulin colocalize (Figure 3.14a). Thus, endogenous CDCA7 localizes at the 
centrosomes during mitosis.  
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The residue threonine (T) 163 of CDCA7 has been noted as a potential 
phosphorylation target of the centrosomal kinase Aurora A. So, the phosphorylation status 
of T163 CDCA7 at the centrosomes was investigated next. The mouse embryonic fibroblast 
cell line NIH 3T3 was synchronized with RO3306, released for 45 minutes and prepared for 
immunofluorescence. Cells are probed for endogenous phospho (p) T163 CDCA7 and γ-
tubulin and then imaged after fluorescence microscopy. Cells found in metaphase and early 
anaphase (sister chromatids at the metaphase plate or sister chromatids that have just begun 
to pull apart from the metaphase plate) show that endogenous pT163 CDCA7 and 
endogenous γ-tubulin colocalize (Figure 3.14b). Thus, CDCA7 is phosphorylated on residue 
T163 at the centrosomes during mitosis. 
TPX2 localizes with microtubule spindles during mitosis, and is highly concentrated 
near the spindle poles (centrosomes). Previous sections have also demonstrated interaction 
between TPX2 and CDCA7. So, TPX2 and CDCA7 may colocalize with one another during 
mitosis. Transiently transfected HEK 293T cells were analyzed after synchronization with 
RO3306, release for one hour and immunofluorescence preparation. Cells found in 
metaphase/anaphase show colocalization of CDCA7 and TPX2 (Figure 3.14c). However, 
CDCA7 appears to also localize as distinct foci at regions adjacent to the centrosomes in HEK 
293T cells (Figure 3.14c). Thus, CDCA7 colocalizes with TPX2 in the mitotic phase of the cell 
cycle.  
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Finally, the phosphorylation status of T163 CDCA7 was investigated during mitosis. 
HEK 293T cells that were transfected with WT FLAG CDCA7 were either left asynchronized 
or were synchronized with RO3306 to the G2/M checkpoint. Synchronized cells were then 
released over various timepoints (0, 0.5, 1, 2 or 3 hours). Samples were either prepared for 
immunofluorescence or lysed, immunoprecipitated (IP) and subjected to western blotting.  
At zero hours of release, there is no detectable pT163 CDCA7 signal, but after one 
hour of release, pT163 CDCA7 is clearly visible as round foci (Figure 3.15a). Expression and 
purification of WT FLAG CDCA7 was detected with an anti-FLAG antibody. WT FLAG CDCA7 
was successfully expressed in all samples, at similar levels (Figure 3.15b). The IPs were also 
positive for pT163 CDCA7 (Figure 3.15b). The ratio of pT163 CDCA7 to total FLAG CDCA7 
was determined for all samples. The ratio at zero hours of release is set to one-fold and the 
other ratios are divided by the ratio at zero hours of release to determine their folds. Within 
30 minutes of release from the G2/M checkpoint, the pT163 CDCA7 level increases by 2-fold 
(Figure 3.15b). Thus, the pT163 CDCA7 level increases as cells progress through mitosis.   
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Figure 3.13: Localization of WT FLAG CDCA7 during mitosis. HEK 293T cells were transfected on 
glass coverslips with WT FLAG CDCA7 for 24 hours. The next day, cells were fixed and probed with 
the indicated antibodies and stained with 4',6-diamidino-2-phenylindole (DAPI). Slides were 
examined via fluorescence microscopy and photographed through a camera. A)  Cell found to be in 
prophase where the nuclear envelope has disappeared, and spindles are beginning to form (DAPI 
image). Staining of FLAG CDCA7 and phospho-T163 CDCA7 is prominent, these regions appear as 
concentrated foci.  B) Cell found in metaphase, DNA can be seen lining up at the metaphase plate 
(DAPI image). FLAG CDCA7 appears to localize at concentrated regions adjacent to the DNA, similar 
to centrosomes.  
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Figure 3.14: CDCA7 colocalization studies during mitosis.  HeLa cells (A), NIH 3T3 cells (B) or HEK 
293T cells transfected with WT FLAG CDCA7 for 24 hours (C) were plated on glass coverslips. Cells 
were incubated with RO3306 for 18 hours to synchronize to the G2/M checkpoint. Following 
synchronization, cells were released for either 40 minutes (A), 45 minutes (B) or 60 minutes (C) and 
then fixed. Cells were later probed with the indicated antibodies and stained with 4',6-diamidino-2-
phenylindole (DAPI). Slides were examined via confocal microscopy (A) or fluorescence microscopy 
(B and C) and photographed through a camera. Images are all false colored. A)  Cell found to be 
transitioning between metaphase and anaphase, sets of DNA are beginning to separate at the 
metaphase plate (DAPI image). Endogenous CDCA7 and γ-tubulin, a centrosomal marker, colocalize. 
Thus, CDCA7 localizes to the centrosomes. B) Cells found at metaphase and early anaphase (DAPI 
image). Endogenous phospho-threonine 163 (pT163) and γ-tubulin colocalize. Therefore, CDCA7 is 
phosphorylated at the centrosome. C) Cell found to be transitioning between metaphase and 
anaphase (DAPI image). Endogenous TPX2 and pT163 CDCA7 colocalize near the regions where 
spindles branch out from the centrosomes (TPX2 image and merge image). Here pT163 CDCA7 also 
localizes as concentrated foci in regions adjacent to TPX2.  
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Figure 3.15: Changes in phosphorylation of T163 CDCA7 during mitosis. A) HEK 293T cells were 
transfected on glass coverslips with WT FLAG CDCA7 for 24 hours. Cells were incubated with RO3306 
for 18 hours to synchronize to the G2/M checkpoint. Following synchronization, cells were either 
fixed immediately or released for one hour and then fixed. Cells were later probed with anti-phospho-
T163 (anti-pT163) and stained with 4',6-diamidino-2-phenylindole (DAPI). Slides were examined via 
fluorescence microscopy and photographed through a camera. At the G2/M checkpoint (0 hours) 
pT163 staining is not detectable but after one hour of release, pT163 staining becomes prominent 
(anti-pT163 image). B) WT FLAG CDCA7 was transfected in HEK 293T cells, left untreated or 
synchronized for 18 hours with RO3306 and released at the indicated time points. Cells were then 
lysed and immunoprecipitated (IP) on anti-FLAG conjugated beads. Top. Here pT163 CDCA7 was 
detected with anti-pT163 CDCA7 immunoblotting. Bottom. Ectopically expressed FLAG constructs 
were identified with anti-FLAG immunoblotting. The ratio of pT163 CDCA7/FLAG CDCA7 is provided 
and this ratio at zero hours of release is set to one-fold. Within 30 minutes, pT163 levels increase by 
two-fold. Abbreviations. AS is asynchronous. 
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Chapter IV: Discussion, Future Directions and Conclusion 
 
Discussion and Future Directions 
 
 CDCA7 was originally defined as a Myc target gene.18 CDCA7 has been shown to be 
overexpressed in a variety of cancers33 and plays a role in neoplastic growth18. Expression 
of CDCA7 is regulated by E2F transcription factors and the C-terminal domain of CDCA7 
contains transcriptional abilities.20 CDCA7 and Myc interact and this interaction is a 
requirement for colony formation and for apoptosis under serum starved conditions. The 
CDCA7-Myc interaction is regulated by Akt phosphorylation and 14-3-3 binding.25 
Understanding the roles CDCA7 plays within the cell may shed light on its oncogenic 
properties. This study focused on identifying novel interactors of CDCA7 through BioID and 
mass spectrometry. The next objective was to verify and characterize a candidate interaction 
through various cell and molecular biology methods.   
 The BioID protocol was optimized for both WT FLAG CDCA7-BirA* and the GFP-BirA* 
control. The experiments were done via transient transfection, however Amber L. Couzens, 
an associate at the Anne-Claude Gingras lab advised the use of stably transfected cell lines, 
which are found to substantially reduce background interactions detected during mass 
spectrometry. Amber L. Couzens has used BioID and immunoprecipitation (IP) experiments 
to map 599 novel interactions.116 The candidate interactor TPX2 was verified through IP 
experiments and the region of interaction was mapped to residues 195-204 of CDCA7. 
Another experiment that can be performed centers around generation of various CDCA7-
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BirA* deletion constructs that are subjected to BioID. Ideally, these experiments would find 
loss of TPX2 biotinylation when residues 195-204 of CDCA7-BirA* are deleted.  
 The residue threonine (T) 163 of CDCA7 conforms to the Aurora A phosphorylation 
consensus site and inhibition of Aurora A kinase was also found to reduce the levels of T163 
phosphorylation. This suggests that CDCA7 is an Aurora A phosphorylation target. One 
question to ask is whether Aurora A phosphorylation impacts the interaction between 
CDCA7 and TPX2. Coexpression of CDCA7 and TPX2 in the presence and absence of Aurora 
A inhibitors may provide answers to this question. Verification of CDCA7 as an Aurora A 
phosphorylation target failed since GST-WT FLAG CDCA7 could not be purified. CDCA7 can 
be cloned with a 6xHis tag and be purified via ion-metal immobilized chromatography 
(IMAC). Once CDCA7 can be purified, in vitro kinase assays can be performed with Aurora A.  
 The phosphorylation of CDCA7 increases during mitosis and this suggests a role for 
CDCA7 during the M phase of the cell cycle. Other cell division cycle associated protein 
(CDCA) family members including CDCA1117, CDCA2118, CDCA3119, CDCA5120 and CDCA8121 
are involved in mitosis. Since CDCA7 interacts with TPX2 and is a potential Aurora A 
phosphorylation target, CDCA7 may play a role in microtubule spindle assembly. 
Consequently, dysregulation of CDCA7 may result in spindle assembly defects, genomic 
instability and account for the oncogenic phenotype seen with CDCA7 overexpression. 
 CDCA7 may instead be a phosphorylation target of Aurora B. Mass spectrometry 
results generated from WT FLAG CDCA7-BirA* have identified several Aurora B associated 
proteins. This includes CDCA2/protein phosphatase 1γ (PP1γ)/Repo-Man. CDCA2 
dephosphorylates histone 3 (H3) at threonine (T) 3, and this dephosphorylation targets 
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Aurora B to chromosomes.122 Another potential interactor, human Spindly, localizes to 
kinetochores via Aurora B.123  
The putative interactor of CDCA7 called regulator of chromatin condensation 2 
(RCC2) shares homology with RCC1 and is a guanine exchange factor (GEF). RCC2 activates 
Ras-like protein A (RalA) which is a GTPase. Interactions between kinetochores and 
microtubules are regulated by Aurora B, RCC2 and RalA and reduction of RCC2 or RalA 
protein downregulates Aurora B activity.124 CDCA8 may also interact with CDCA7. CDCA8 is 
part of the chromosome passenger complex (CPC) and binds with Aurora B interactors 
Survivin and INCENP. Knockdown of CDCA8 leads to deregulation of kinetochore-
chromosome attachment which leads to defects in chromosome segregation.121 TPX2 also 
mediates Aurora B activation. Immunodepletion of TPX2 reduces the Aurora B-Survivin or 
Aurora B-INCENP interactions, while TPX2 overexpression has the opposite effect.125 Thus, 
experiments investigating the effects of Aurora B on CDCA7 should be considered.  
The localization pattern of Aurora B is chromosomal (prophase), centromeric 
(metaphase) and midzone (anaphase).126 CDCA7 on the other hand localizes at centrosomes 
during prophase, metaphase and anaphase and is phosphorylated at the centrosomes. The 
localization of CDCA7 coincides more with Aurora A81, so CDCA7 is more likely to be an 
Aurora A kinase phosphorylation target. However, CDCA7 localizes at the centrosomes while 
the TPX2-AurA complex localizes to branching microtubules81. How can this complex 
phosphorylate CDCA7 at the centrosome? This may be contingent on the mitotic phase 
where CDCA7 is phosphorylated. For example, during prometaphase, the centrosomes 
(CDCA7) and branching microtubules (TPX2-AurA complex), where microtubule nucleation 
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events occur, are in close proximity.74 During this time, CDCA7 may interact with the TPX2-
AurA complex. Aurora A can then phosphorylate CDCA7 at T163. Several centrosomal target 
proteins of Aurora A cannot be phosphorylated in the absence of TPX2. One example is the 
transforming acid coiled coil 3 protein (TACC3).127 Thus, the TPX2-AurA complex likely 
regulates the phosphorylation status of residue T163 of CDCA7, based on the evidence 
provided in this study and findings in scientific literature.  
Aurora A phosphorylation targets were also identified through mass spectrometry 
such as cofilin-1128. The putative interactor DLGAP5, also known as hepatoma Up-regulated 
protein (HURP), is a known oncogene that plays a role in hepatocellular carcinomas.129 HURP 
localization is RanGTP dependent130 and HURP is a TPX2-AurA complex regulated protein131. 
Aurora A phosphorylation stabilizes HURP.131 Overexpression of HURP also leads to spindle 
defects and HURP can arrest cells at the spindle checkpoint. The N- and C-terminal domains 
of unphosphorylated HURP interact and this interaction is disrupted by phosphorylation of 
HURP at the C-terminal by Aurora A. The N-terminal domain of HURP then binds to 
microtubules and stabilizes them. Dysregulation of HURP permits spindle checkpoint 
evasion and is thought to be a major cause of TPX2-AurA complex mediated oncogenesis.132 
So, verification of CDCA7-HURP interaction would provide another line of evidence for 
CDCA7 regulation via the TPX2-AurA complex.  
CDCA7 has been defined as a phosphorylation target of Akt.25 Active Akt, 
phosphorylated at threonine (T) 308, also localizes to centrosomes during mitosis. The levels 
of phospho-T308 Akt increase during prophase, peak at metaphase and return to basal levels 
following chromosome segregation.133 The effect of Akt inhibition on the phosphorylation 
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status of residue T163 of CDCA7 should be considered. The possibility of Akt and CDCA7 
colocalization during mitosis should also be investigated.  
A theory postulates that target genes of Myc lead to the phenotypic outcomes of Myc 
expression, including tumorigenesis.33 CDCA7 is an established target gene of Myc.18 ChIP 
experiments have shown direct interaction between Myc and the Myc E-box at the 
transcription start site (TTS) of the Aurora A promoter. Myc also positively regulates Aurora 
A gene expression.134 Myc is correlated with 70% of cancers.15 Amplification of chromosome 
20q where Aurora A and TPX2 genes reside coincide with amplification of chromosome 8q 
where the Myc gene resides, in colorectal cancers. In assays for colony growth in soft agar, 
overexpression of Aurora A, TPX2 and Myc results in violent anchorage-independent 
growth.135  
CDCA7 has also been shown to be overexpressed in numerous cancers including 
colorectal cancer. Upregulation of CDCA7 and Myc has been demonstrated in colorectal 
cancer patients.33 The human protein atlas (HPA) has reported CDCA7 dysregulation in 597 
colorectal cancer cases. While 124 patients have passed away (21%), 473 patients are still 
alive (79%). Unfortunately, 64% of remaining patients have low probability of survival (301 
cases).136 Accordingly, future experiments should investigate the effects of Myc, Aurora A 
kinase and TPX2 on CDCA7 in the context of colon carcinoma (HCT116) and adenoma (DLD-
1) cell lines. 
In hepatocellular carcinomas (HCCs), ChIP experiments have demonstrated binding 
of Myc to the Aurora A promoter and Myc also transcriptionally activates Aurora A in HCCs. 
Aurora A has also been shown to bind to the Myc gene. Aurora A binds to the nuclear 
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hypersensitive element III(1) and increases Myc expression.137 However, NHEIII(1) has been 
shown to negatively regulate Myc expression138, so Aurora A may negatively regulate this 
region137. Expression of Aurora A and Myc are linked and increasing concentrations of 
Aurora A kinase in the nucleus lead to increases in Myc mRNA expression.137 TPX2 is also 
overexpressed in HCCs and inhibition of TPX2 expression results in decreases in cell 
proliferation and invasion.139  
Interestingly, while mRNA analysis of CDCA7 in HCCs has not been directly reported, 
the HPA has identified dysregulation of CDCA7 as a poor prognosis marker for liver cancers. 
There are 365 documented cases of CDCA7 deregulation in liver cancer patients. Out of the 
365 reported cases found in the HPA, only 64% of patients are currently alive and 36% of 
patients are dead. From the remaining 235 cases, 79% of patients have low predicted 
probability of survival.136 Consequently, CDCA7 regulation and expression with respect to 
Myc, Aurora A kinase and TPX2 in HCC cell lines such as HepG2 and BEL-7402 should be 
considered.   
Conclusion 
 
Aurora A kinase and its activator TPX2 play integral roles during mitosis.105 Null mice 
of Aurora A and TPX2 are embryonically lethal and have defects in spindle assembly and 
chromosome segregation.59,86 Both Aurora A and TPX2 are potent oncogenes that promote 
genomic instability and drive tumorigenesis.75 The TPX2-AurA complex is regulated by the 
RanGTP gradient and localizes to microtubules where Aurora A phosphorylates target 
proteins. The phosphorylation targets of Aurora A mediate microtubule nucleation and leads 
to spindle assembly, chromosome segregation and ultimately proper cell division.105 
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Discerning the roles of the TPX2-AurA complex targets is required to delineate the process 
of spindle assembly and its dysregulation. 
 The study presented here has demonstrated that CDCA7 and TPX2 directly interact 
with each other. The acidic amino acid residues within residues 195-204 of CDCA7 may 
provide the mode of interaction between these two proteins. Inhibitor experiments suggest 
that Aurora A kinase phosphorylates CDCA7 at the residue T163. CDCA7 has been shown to 
localize to the centrosome during mitosis and is phosphorylated  at the centrosomes.  CDCA7 
has been shown to colocalize with TPX2 around the centrosomes. Thus, during mitosis, 
CDCA7 at the centrosome may interact with TPX2 at branching microtubules. Interaction of 
CDCA7 and TPX2 brings active Aurora A near CDCA7. Aurora A can then phosphorylate 
CDCA7 at T163. Figure 4.1 provides an overview of this study’s findings and theories. 
 Future experiments should consider the significance of CDCA7 T163 phosphorylation 
during mitosis. As CDCA7 interacts with TPX2 and is potentially regulated by Aurora A, it 
may be involved in spindle assembly. Interaction of CDCA7 with other TPX2-AurA complex 
targets should be investigated. The effect of CDCA7 knockdown or the effect of loss of 
function mutant T163A CDCA7 on spindle assembly should be considered. The possibility of 
Aurora B or Akt regulation of CDCA7 during mitosis should also be examined. Finally, the 
effects of Myc, Aurora A kinase and TPX2 on CDCA7 should also be studied in colorectal and 
liver cancers. These findings shed light on the interactions and regulation of CDCA7 and 
define the CDCA7 protein in normal physiological contexts. The information here will 
facilitate points of reference when investigating the role of CDCA7 in dysregulated processes, 
such as tumorigenesis.  
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Figure 4.1: CDCA7, TPX2 and Aurora A model. Zoomed out. Cell in the mitotic phase of the cell cycle. 
Zoomed in. During mitosis, CDCA7 localizes to the centrosomes. TPX2 bound to microtubules also 
binds with Aurora A. TPX2 binding allows Aurora A to autophosphorylate and activate itself. TPX2 
also directly interacts with CDCA7. Aurora A, complexed with TPX2, phosphorylates CDCA7 at 
threonine (T) 163.  
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Appendices 
 
Appendix A: Generation of BirA* Constructs 
 
Abridged Version 
Three BirA* constructs of particular interest were generated for BioID. These constructs are 
WT FLAG CDCA7-BirA*, T163A FLAG CDCA7-BirA* and c-Myc-BirA*.  
Methods 
Polymerase Chain Reaction (PCR): The genes encoding WT FLAG CDCA7 and T163A FLAG 
CDCA7 in the pCMV-3X-FLAG vector and c-Myc in the pcDNA 3.0 vector were subjected to 
the Q5 PCR protocol, as detailed in Chapter 2. The forward and reverse primers for WT FLAG 
CDCA7 and T163A FLAG CDCA7 were identical and introduced AgeI and BspEI restriction 
enzyme cut sites at the 5’ and 3’ ends of the PCR products, respectively. The forward and 
reverse primers for c-Myc introduced the restriction enzyme cut site AgeI at the 5’ end and 
BamHI at the 3’ end of its PCR product. 
Restriction Enzyme Digests: Restriction enzyme digestion followed the general protocol 
outlined in Chapter 2. The blunt end PCR products of WT FLAG CDCA7 and T163A FLAG 
CDCA7, as well pcDNA 3.1 MCS-BirA(R118G)-HA (BirA* backbone vector) were subjected to 
partial restriction digests with AgeI (NEB Catalog# R0552) in NEBuffer™ 1.1 (NEB Catalog# 
B7201) for 30 minutes at 37°C, followed by restriction digest with BspEI (NEB Catalog# 
R0540) in NEBuffer™ 3.1 (NEB Catalog# B7203) for 30 minutes at 37°C. The blunt end PCR 
product of c-Myc and the BirA* backbone vector were subjected to double restriction digests 
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with AgeI (NEB Catalog# R0552) and BamHI (NEB Catalog# R0136) in Cut Smart® Buffer 
(NEB Catalog# B7204) for 1 hour at 37°C. To verify positive ligations, miniprepped DNA from 
colonies of WT FLAG CDCA7-BirA* and T163A FLAG CDCA7-BirA* ligations were double 
digested with NheI (NEB Catalog# R0131) and XhoI (NEB Catalog# R0146) in Cut Smart® 
Buffer at 37°C for 1 hour. For c-Myc BirA*, miniprepped DNA from ligation reaction colonies 
were double digested with NheI and ClaI (NEB Catalog# R0147) in Cut Smart® Buffer at 37°C 
for 1 hour. The T163A mutation in CDCA7 was engineered to incorporate a BssHII cut site 
not present in the WT CDCA7 gene. Verification of the T163A deletion was done via 
restriction digest of BssHII (NEB Catalog# R0199) in Cut Smart® Buffer at 37°C for 1 hour.    
Results 
In order to generate the plasmids containing WT FLAG CDCA7-BirA*, T163A FLAG CDCA7-
BirA* and c-Myc-BirA*, the PCR products of WT FLAG CDCA7, T163A FLAG CDCA7 and c-
Myc were generated with primers that included restriction enzyme sites at their 5’ and 3’ 
ends (Figure A.1a). The PCR products were then purified from agarose gels, subjected to 
restriction digests along with the BirA* backbone vector and once again purified from 
agarose gels (Figure A.1b). The restriction digested desired insert and BirA* backbone 
vectors were ligated with one another and transformed into DH5α E. coli cells. Colonies 
were selected, miniprepped and subjected to restriction digests in order to verify inserts 
(Figure A.2, A.3). T163A mutation of the CDCA7 gene was also confirmed with restriction 
enzyme digestion (Figure A.4). Positive colonies were then midiprepped and sequence 
verified.  
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Figure A.1: Polymerase Chain Reaction (PCR) and Restriction Enzyme Digestions of BirA* construct 
gene insertions. PCR of desired gene inserts. The abbreviation kbps stands for kilo base pairs.  A) WT 
CDCA7 and T163A CDCA7 which resided in the pCMV-3X-FLAG vector and c-Myc which resided in 
the pcDNA 3.0 vector were subjected to PCR. The primers used for PCR engineered unique restriction 
enzyme (RE) sites AGE1 and BSPE1 into the 5’ and 3’ ends of WT/T163A FLAG-CDCA7 (1116 bps). 
The PCR primers for c-Myc (1365 bps) introduced unique 5’ AGE1 and 3’ BAMH1 RE sites to c-Myc. 
All PCR products were purified with a gel extraction kit. B) The WT FLAG-CDCA7 and T163A FLAG-
CDCA7 PCR products were sequentially digested with RE AgeI and BspEI. The c-Myc PCR product and 
BirA* vector backbone (6382 bps) were co-digested with AgeI and BamHI. The BirA* backbone was 
also sequentially digested with AgeI and BspEI on another gel (not shown). All digested products 
were purified with a gel extraction kit. 
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Figure A.2: Screen for positive ligation reactions of WT/T163A CDCA7-BirA*. Following ligation, 
Numbered columns indicate the order in which colonies were chosen. The abbreviation kbps stands 
for kilo base pairs.  DNA was transformed and ten colonies from each transformation were selected, 
miniprepped and subjected to restriction enzyme (RE) double digests. The digests were designed to 
cut once in the inserted gene and once in the BirA* vector backbone. A) and B) WT FLAG CDCA7-
BirA* and T163A FLAG CDCA7-BirA* were digested with NheI and XhoI. Positive colonies consisted 
of two fragments, with sizes 6692 bps and 792 bps.   Colony 7 (black box) was selected for WT FLAG-
CDCA7-BirA* and colony 6 (black box) was selected for T163A FLAG-CDCA7-BirA* and were verified 
with sequencing. The negative control in A) consisted of the BirA* backbone alone. 
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Figure A.3: Screen for positive ligation reactions of c-Myc-BirA*. Following ligation, Numbered 
columns indicate the order in which colonies were chosen. The abbreviation kbps stands for kilo base 
pairs.  DNA was transformed and ten colonies from each transformation were selected, miniprepped 
and subjected to restriction enzyme (RE) double digests. The digests were designed to cut once in 
the inserted gene and once in the BirA* vector backbone. NheI and ClaI were used to digest c-Myc-
BirA*. Positive colonies consisted of two fragments, with sizes 6881 bps and 852 bps. Colony 2 (black 
box) was selected and verified with sequencing. The negative control consisted of the BirA* backbone 
alone. The positive control consisted of a Myc-BirA* construct that was previously cloned by another 
lab member. 
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Figure A.4: Confirmation of T163A mutagenesis of the CDCA7 gene. The abbreviation kbps stands 
for kilo base pairs. To confirm that T163A CDCA7-BirA* contained the T163A mutation, restriction 
digest was performed with BssHII. The T163A mutation was designed with a uniquely engineered 
restriction enzyme site for BssHII, which would distinguish it from WT FLAG CDCA7. BssHII is a 
unique restriction enzyme site in the pCMV-3X-FLAG vector and BirA* backbone vector.  WT FLAG 
CDCA7 in the pCMV-3X-FLAG vector (7489 bps) was used as negative control as it lacks the BssHII 
cut site in the CDCA7 gene. T163A (TA) FLAG CDCA7 was used as a positive control and generates 
two fragments (2201 bps and 5288 bps). Miniprep and midiprep DNA of T163A CDCA7-BirA* tested 
positive of BssHII digestions, generating two fragments at 3313 bps and 4171 bps.  
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Appendix B: Generation of TPX2 Construct 
 
Abridged Version 
For ectopic expression of wild-type TPX2 under the regulation of a CMV promoter, 
wild-type TPX2 was excised from a mCherry plasmid containing TPX2 and inserted into the 
plasmid pcDNA3.1/Hygro(+). 
Methods 
Restriction Enzyme Digests: Restriction enzyme digestion followed the general protocol 
outlined in Chapter 2. The plasmid DNA from pmCherry-TPX2 and pcDNA3.1/Hygro(+) were 
both subjected to double restriction enzyme digests. Both plasmids were cut with HindIII 
(NEB Catalog# R0104) and BamHI (NEB Catalog# R0136) in NEBuffer™ 2.1 (NEB Catalog# 
B7202) for 1 hour at 37°C. Verification of wild-type TPX2 insertion into pcDNA3.1/Hygro(+) 
following ligation was also done with the same combination of restriction enzymes. 
Results 
To produce a plasmid that solely expressed the wild-type TPX2 gene, the plasmids 
pmCherry-TPX2 which contained the TPX2 wild-type gene and pcDNA 3.1/Hygro(+) which 
contained the CMV promoter were subjected to double restriction enzyme digestion (Figure 
B.1a), purified from agarose gels and subjected to ligation reactions. Ligated DNA was 
transformed, colonies were picked, miniprepped and screened with restriction enzyme 
digestion (Figure B.1b). A positive colony was picked, midiprepped and sent for sequencing 
where insertion was verified.  
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Figure B.1: Construction of wild-type TPX2 plasmid. Plasmid generation entailed two steps: excision 
of wild-type TPX2 from the pmCherry-TPX2 plasmid and insertion of wild-type TPX2 into the 
pcDNA3.1/Hygro(+) plasmid. A) Both pmCherry-TPX2 and pcDNA3.1/Hygro(+) were restriction 
enzyme digested with HindIII and BamHI. A band between 3-2 kilo base pairs (kbps) matches the 
size of wild-type TPX2 (2.3 kbps) and is indicated in the white box. Both wild-type TPX2 (white box) 
and pcDNA3.1/Hygro(+) were purified following restriction digests for the upcoming cloning stages. 
B) Wild-type TPX2 and pcDNA3.1/Hygro(+) were ligated and transformed. A sample of transformed 
colonies were miniprepped and subject to restriction digest with HindIII and BamHI. Insertion of 
TPX2 was confirmed by the presence of a 2.3 kbps fragment. A positive colony (white box) was 
transformed and midiprepped. Wild-type TPX2 insertion was verified through sequencing. 
Numbered columns indicate the order in which colonies were picked. 
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